{"transactions":[{"id":4615627,"issuer":{"id":9597,"kind":"organization","name":"Barinthus Biotherapeutics plc.","symbol":"BRNS"},"owners":[{"id":74731,"kind":"organization","name":"Oxford Science Enterprises plc","position":1,"cik":"0001856079","reported_name":"Oxford Science Enterprises plc","relationship":{"director":false,"officer":false,"ten_percent_owner":false,"other":true,"other_text":"former 10% owner"}}],"security":"Ordinary Shares","published_at":"2026-09-11T15:00:41.000Z","date":"2026-09-09","kind":"other","planned":false,"acquired":false,"shares":8797770,"price":0.111,"value":976552.47,"ownership":{"direct":true},"footnotes":[{"field":"security","element":"securityTitle","label":"F1","text":"Ordinary Shares may be represented by American Depositary Shares, each of which represents one Ordinary Share."},{"field":"price","element":"transactionPricePerShare","label":"F2","text":"Pursuant to the terms of the Merger Agreement between Barinthus Biotherapeutics plc (the \"Issuer\") and Clywedog Therapeutics, Inc., the Issuer's board of directors has determined that each of the Issuer's outstanding Ordinary Shares (represented by American Depositary Shares) will be converted into the right to receive 0.111 shares of Beacon Topco, Inc.'s common stock, plus cash in lieu of any fractional shares resulting from the exchange, in accordance with the scheme of arrangement."}],"balance_after":0,"source":{"system":"sec-edgar","filing":"0001856079-26-000002","document":"primary_doc.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1856079/000185607926000002/primary_doc.xml","form_type":"4/A","original_submission_date":"2021-05-06"}},{"id":4613376,"issuer":{"id":9597,"kind":"organization","name":"Barinthus Biotherapeutics plc.","symbol":"BRNS"},"owners":[{"id":78627,"kind":"person","name":"Wright Robin","position":1,"cik":"0001851640","reported_name":"Wright Robin","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Share Option (Right to Buy)","published_at":"2026-09-09T20:21:03.000Z","date":"2026-09-09","kind":"disposition_to_issuer","planned":false,"acquired":false,"shares":20174,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F2","text":"This Form 4 reports securities transacted in connection with the Agreement and Plan of Merger, dated September 29, 2025, as amended (the \"Merger Agreement\") by and among the Issuer, Beacon Topco, Inc. (\"Topco\"), a Delaware corporation and a direct wholly owned subsidiary of the Issuer, Cdog Merger Sub, Inc., a Delaware corporation and a direct wholly owned subsidiary of Topco, and Clywedog Therapeutics, Inc., a Delaware corporation. On September 9, 2026 (the \"Effective Time\"), in connection with the effectiveness of the scheme of arrangement under Part 26 of the United Kingdom Companies Act 2006 (the \"Scheme\") contemplated by the Merger Agreement, Topco acquired the entire issued share capital of the Issuer, resulting in the Issuer becoming a direct wholly owned subsidiary of Topco."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F4","text":"Pursuant to the Merger Agreement, at the Effective Time, each option to acquire Shares under the Issuer's equity plans that was outstanding as of immediately prior to the Effective Time ceased to represent a right to acquire Shares of the Issuer, and was converted into an option to acquire shares of Topco Common Stock and assumed by Topco on the same terms and conditions (including applicable vesting and exercisability conditions) as were applicable to such option immediately prior to the Effective Time."},{"field":"derivative.underlying","element":"underlyingSecurityTitle","label":"F1","text":"The Ordinary Shares may be represented by American Depositary Shares (\"ADSs\" and together with the Ordinary Shares, the \"Shares\"), each of which currently represents one Ordinary Share."}],"balance_after":0,"derivative":{"exercise_price":1,"expiration_date":"2035-06-10","underlying":"Ordinary Shares","underlying_shares":20174},"source":{"system":"sec-edgar","filing":"0001104659-26-106343","document":"tm2625057-8_4seq1.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":7,"url":"https://www.sec.gov/Archives/edgar/data/1851640/000110465926106343/tm2625057-8_4seq1.xml","form_type":"4"}},{"id":4613375,"issuer":{"id":9597,"kind":"organization","name":"Barinthus Biotherapeutics plc.","symbol":"BRNS"},"owners":[{"id":78627,"kind":"person","name":"Wright Robin","position":1,"cik":"0001851640","reported_name":"Wright Robin","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Share Option (Right to Buy)","published_at":"2026-09-09T20:21:03.000Z","date":"2026-09-09","kind":"disposition_to_issuer","planned":false,"acquired":false,"shares":19516,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F2","text":"This Form 4 reports securities transacted in connection with the Agreement and Plan of Merger, dated September 29, 2025, as amended (the \"Merger Agreement\") by and among the Issuer, Beacon Topco, Inc. (\"Topco\"), a Delaware corporation and a direct wholly owned subsidiary of the Issuer, Cdog Merger Sub, Inc., a Delaware corporation and a direct wholly owned subsidiary of Topco, and Clywedog Therapeutics, Inc., a Delaware corporation. On September 9, 2026 (the \"Effective Time\"), in connection with the effectiveness of the scheme of arrangement under Part 26 of the United Kingdom Companies Act 2006 (the \"Scheme\") contemplated by the Merger Agreement, Topco acquired the entire issued share capital of the Issuer, resulting in the Issuer becoming a direct wholly owned subsidiary of Topco."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F4","text":"Pursuant to the Merger Agreement, at the Effective Time, each option to acquire Shares under the Issuer's equity plans that was outstanding as of immediately prior to the Effective Time ceased to represent a right to acquire Shares of the Issuer, and was converted into an option to acquire shares of Topco Common Stock and assumed by Topco on the same terms and conditions (including applicable vesting and exercisability conditions) as were applicable to such option immediately prior to the Effective Time."},{"field":"derivative.underlying","element":"underlyingSecurityTitle","label":"F1","text":"The Ordinary Shares may be represented by American Depositary Shares (\"ADSs\" and together with the Ordinary Shares, the \"Shares\"), each of which currently represents one Ordinary Share."}],"balance_after":0,"derivative":{"exercise_price":2.34,"expiration_date":"2034-05-10","underlying":"Ordinary Shares","underlying_shares":19516},"source":{"system":"sec-edgar","filing":"0001104659-26-106343","document":"tm2625057-8_4seq1.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":6,"url":"https://www.sec.gov/Archives/edgar/data/1851640/000110465926106343/tm2625057-8_4seq1.xml","form_type":"4"}},{"id":4613374,"issuer":{"id":9597,"kind":"organization","name":"Barinthus Biotherapeutics plc.","symbol":"BRNS"},"owners":[{"id":78627,"kind":"person","name":"Wright Robin","position":1,"cik":"0001851640","reported_name":"Wright Robin","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Share Option (Right to Buy)","published_at":"2026-09-09T20:21:03.000Z","date":"2026-09-09","kind":"disposition_to_issuer","planned":false,"acquired":false,"shares":19197,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F2","text":"This Form 4 reports securities transacted in connection with the Agreement and Plan of Merger, dated September 29, 2025, as amended (the \"Merger Agreement\") by and among the Issuer, Beacon Topco, Inc. (\"Topco\"), a Delaware corporation and a direct wholly owned subsidiary of the Issuer, Cdog Merger Sub, Inc., a Delaware corporation and a direct wholly owned subsidiary of Topco, and Clywedog Therapeutics, Inc., a Delaware corporation. On September 9, 2026 (the \"Effective Time\"), in connection with the effectiveness of the scheme of arrangement under Part 26 of the United Kingdom Companies Act 2006 (the \"Scheme\") contemplated by the Merger Agreement, Topco acquired the entire issued share capital of the Issuer, resulting in the Issuer becoming a direct wholly owned subsidiary of Topco."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F4","text":"Pursuant to the Merger Agreement, at the Effective Time, each option to acquire Shares under the Issuer's equity plans that was outstanding as of immediately prior to the Effective Time ceased to represent a right to acquire Shares of the Issuer, and was converted into an option to acquire shares of Topco Common Stock and assumed by Topco on the same terms and conditions (including applicable vesting and exercisability conditions) as were applicable to such option immediately prior to the Effective Time."},{"field":"derivative.underlying","element":"underlyingSecurityTitle","label":"F1","text":"The Ordinary Shares may be represented by American Depositary Shares (\"ADSs\" and together with the Ordinary Shares, the \"Shares\"), each of which currently represents one Ordinary Share."}],"balance_after":0,"derivative":{"exercise_price":2.27,"expiration_date":"2033-05-11","underlying":"Ordinary Shares","underlying_shares":19197},"source":{"system":"sec-edgar","filing":"0001104659-26-106343","document":"tm2625057-8_4seq1.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":5,"url":"https://www.sec.gov/Archives/edgar/data/1851640/000110465926106343/tm2625057-8_4seq1.xml","form_type":"4"}},{"id":4613373,"issuer":{"id":9597,"kind":"organization","name":"Barinthus Biotherapeutics plc.","symbol":"BRNS"},"owners":[{"id":78627,"kind":"person","name":"Wright Robin","position":1,"cik":"0001851640","reported_name":"Wright Robin","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Share Option (Right to Buy)","published_at":"2026-09-09T20:21:03.000Z","date":"2026-09-09","kind":"disposition_to_issuer","planned":false,"acquired":false,"shares":18604,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F2","text":"This Form 4 reports securities transacted in connection with the Agreement and Plan of Merger, dated September 29, 2025, as amended (the \"Merger Agreement\") by and among the Issuer, Beacon Topco, Inc. (\"Topco\"), a Delaware corporation and a direct wholly owned subsidiary of the Issuer, Cdog Merger Sub, Inc., a Delaware corporation and a direct wholly owned subsidiary of Topco, and Clywedog Therapeutics, Inc., a Delaware corporation. On September 9, 2026 (the \"Effective Time\"), in connection with the effectiveness of the scheme of arrangement under Part 26 of the United Kingdom Companies Act 2006 (the \"Scheme\") contemplated by the Merger Agreement, Topco acquired the entire issued share capital of the Issuer, resulting in the Issuer becoming a direct wholly owned subsidiary of Topco."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F4","text":"Pursuant to the Merger Agreement, at the Effective Time, each option to acquire Shares under the Issuer's equity plans that was outstanding as of immediately prior to the Effective Time ceased to represent a right to acquire Shares of the Issuer, and was converted into an option to acquire shares of Topco Common Stock and assumed by Topco on the same terms and conditions (including applicable vesting and exercisability conditions) as were applicable to such option immediately prior to the Effective Time."},{"field":"derivative.underlying","element":"underlyingSecurityTitle","label":"F1","text":"The Ordinary Shares may be represented by American Depositary Shares (\"ADSs\" and together with the Ordinary Shares, the \"Shares\"), each of which currently represents one Ordinary Share."}],"balance_after":0,"derivative":{"exercise_price":4.27,"expiration_date":"2032-06-15","underlying":"Ordinary Shares","underlying_shares":18604},"source":{"system":"sec-edgar","filing":"0001104659-26-106343","document":"tm2625057-8_4seq1.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":4,"url":"https://www.sec.gov/Archives/edgar/data/1851640/000110465926106343/tm2625057-8_4seq1.xml","form_type":"4"}},{"id":4613372,"issuer":{"id":9597,"kind":"organization","name":"Barinthus Biotherapeutics plc.","symbol":"BRNS"},"owners":[{"id":78627,"kind":"person","name":"Wright Robin","position":1,"cik":"0001851640","reported_name":"Wright Robin","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Share Option (Right to Buy)","published_at":"2026-09-09T20:21:03.000Z","date":"2026-09-09","kind":"disposition_to_issuer","planned":false,"acquired":false,"shares":34328,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F2","text":"This Form 4 reports securities transacted in connection with the Agreement and Plan of Merger, dated September 29, 2025, as amended (the \"Merger Agreement\") by and among the Issuer, Beacon Topco, Inc. (\"Topco\"), a Delaware corporation and a direct wholly owned subsidiary of the Issuer, Cdog Merger Sub, Inc., a Delaware corporation and a direct wholly owned subsidiary of Topco, and Clywedog Therapeutics, Inc., a Delaware corporation. On September 9, 2026 (the \"Effective Time\"), in connection with the effectiveness of the scheme of arrangement under Part 26 of the United Kingdom Companies Act 2006 (the \"Scheme\") contemplated by the Merger Agreement, Topco acquired the entire issued share capital of the Issuer, resulting in the Issuer becoming a direct wholly owned subsidiary of Topco."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F4","text":"Pursuant to the Merger Agreement, at the Effective Time, each option to acquire Shares under the Issuer's equity plans that was outstanding as of immediately prior to the Effective Time ceased to represent a right to acquire Shares of the Issuer, and was converted into an option to acquire shares of Topco Common Stock and assumed by Topco on the same terms and conditions (including applicable vesting and exercisability conditions) as were applicable to such option immediately prior to the Effective Time."},{"field":"derivative.underlying","element":"underlyingSecurityTitle","label":"F1","text":"The Ordinary Shares may be represented by American Depositary Shares (\"ADSs\" and together with the Ordinary Shares, the \"Shares\"), each of which currently represents one Ordinary Share."}],"balance_after":0,"derivative":{"exercise_price":17,"expiration_date":"2031-05-01","underlying":"Ordinary Shares","underlying_shares":34328},"source":{"system":"sec-edgar","filing":"0001104659-26-106343","document":"tm2625057-8_4seq1.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":3,"url":"https://www.sec.gov/Archives/edgar/data/1851640/000110465926106343/tm2625057-8_4seq1.xml","form_type":"4"}},{"id":4613371,"issuer":{"id":9597,"kind":"organization","name":"Barinthus Biotherapeutics plc.","symbol":"BRNS"},"owners":[{"id":78627,"kind":"person","name":"Wright Robin","position":1,"cik":"0001851640","reported_name":"Wright Robin","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Share Option (Right to Buy)","published_at":"2026-09-09T20:21:03.000Z","date":"2026-09-09","kind":"disposition_to_issuer","planned":false,"acquired":false,"shares":20394,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F2","text":"This Form 4 reports securities transacted in connection with the Agreement and Plan of Merger, dated September 29, 2025, as amended (the \"Merger Agreement\") by and among the Issuer, Beacon Topco, Inc. (\"Topco\"), a Delaware corporation and a direct wholly owned subsidiary of the Issuer, Cdog Merger Sub, Inc., a Delaware corporation and a direct wholly owned subsidiary of Topco, and Clywedog Therapeutics, Inc., a Delaware corporation. On September 9, 2026 (the \"Effective Time\"), in connection with the effectiveness of the scheme of arrangement under Part 26 of the United Kingdom Companies Act 2006 (the \"Scheme\") contemplated by the Merger Agreement, Topco acquired the entire issued share capital of the Issuer, resulting in the Issuer becoming a direct wholly owned subsidiary of Topco."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F4","text":"Pursuant to the Merger Agreement, at the Effective Time, each option to acquire Shares under the Issuer's equity plans that was outstanding as of immediately prior to the Effective Time ceased to represent a right to acquire Shares of the Issuer, and was converted into an option to acquire shares of Topco Common Stock and assumed by Topco on the same terms and conditions (including applicable vesting and exercisability conditions) as were applicable to such option immediately prior to the Effective Time."},{"field":"derivative.underlying","element":"underlyingSecurityTitle","label":"F1","text":"The Ordinary Shares may be represented by American Depositary Shares (\"ADSs\" and together with the Ordinary Shares, the \"Shares\"), each of which currently represents one Ordinary Share."}],"balance_after":0,"derivative":{"exercise_price":0.0001,"expiration_date":"2030-01-07","underlying":"Ordinary Shares","underlying_shares":20394},"source":{"system":"sec-edgar","filing":"0001104659-26-106343","document":"tm2625057-8_4seq1.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1851640/000110465926106343/tm2625057-8_4seq1.xml","form_type":"4"}},{"id":4613370,"issuer":{"id":9597,"kind":"organization","name":"Barinthus Biotherapeutics plc.","symbol":"BRNS"},"owners":[{"id":78627,"kind":"person","name":"Wright Robin","position":1,"cik":"0001851640","reported_name":"Wright Robin","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Ordinary Shares","published_at":"2026-09-09T20:21:03.000Z","date":"2026-09-09","kind":"disposition_to_issuer","planned":false,"acquired":false,"shares":48256,"ownership":{"direct":true},"footnotes":[{"field":"security","element":"securityTitle","label":"F1","text":"The Ordinary Shares may be represented by American Depositary Shares (\"ADSs\" and together with the Ordinary Shares, the \"Shares\"), each of which currently represents one Ordinary Share."},{"field":"kind","element":"transactionCoding","label":"F2","text":"This Form 4 reports securities transacted in connection with the Agreement and Plan of Merger, dated September 29, 2025, as amended (the \"Merger Agreement\") by and among the Issuer, Beacon Topco, Inc. (\"Topco\"), a Delaware corporation and a direct wholly owned subsidiary of the Issuer, Cdog Merger Sub, Inc., a Delaware corporation and a direct wholly owned subsidiary of Topco, and Clywedog Therapeutics, Inc., a Delaware corporation. On September 9, 2026 (the \"Effective Time\"), in connection with the effectiveness of the scheme of arrangement under Part 26 of the United Kingdom Companies Act 2006 (the \"Scheme\") contemplated by the Merger Agreement, Topco acquired the entire issued share capital of the Issuer, resulting in the Issuer becoming a direct wholly owned subsidiary of Topco."},{"field":"shares","element":"transactionShares","label":"F3","text":"Pursuant to the Merger Agreement and in connection with the effectiveness of the Scheme, at the Effective Time, each Share of the Issuer was converted into the right to receive 0.111 shares of common stock, $0.0001 par value per share, of Topco (the \"Topco Common Stock\")."},{"field":"price","element":"transactionPricePerShare","label":"F3","text":"Pursuant to the Merger Agreement and in connection with the effectiveness of the Scheme, at the Effective Time, each Share of the Issuer was converted into the right to receive 0.111 shares of common stock, $0.0001 par value per share, of Topco (the \"Topco Common Stock\")."}],"balance_after":0,"source":{"system":"sec-edgar","filing":"0001104659-26-106343","document":"tm2625057-8_4seq1.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1851640/000110465926106343/tm2625057-8_4seq1.xml","form_type":"4"}},{"id":4613369,"issuer":{"id":9597,"kind":"organization","name":"Barinthus Biotherapeutics plc.","symbol":"BRNS"},"owners":[{"id":78630,"kind":"person","name":"Scheeren Joseph","position":1,"cik":"0001852070","reported_name":"Scheeren Joseph","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Share Option (Right to Buy)","published_at":"2026-09-09T20:20:33.000Z","date":"2026-09-09","kind":"disposition_to_issuer","planned":false,"acquired":false,"shares":20174,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F2","text":"This Form 4 reports securities transacted in connection with the Agreement and Plan of Merger, dated September 29, 2025, as amended (the \"Merger Agreement\") by and among the Issuer, Beacon Topco, Inc. (\"Topco\"), a Delaware corporation and a direct wholly owned subsidiary of the Issuer, Cdog Merger Sub, Inc., a Delaware corporation and a direct wholly owned subsidiary of Topco, and Clywedog Therapeutics, Inc., a Delaware corporation. On September 9, 2026 (the \"Effective Time\"), in connection with the effectiveness of the scheme of arrangement under Part 26 of the United Kingdom Companies Act 2006 (the \"Scheme\") contemplated by the Merger Agreement, Topco acquired the entire issued share capital of the Issuer, resulting in the Issuer becoming a direct wholly owned subsidiary of Topco."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F4","text":"Pursuant to the Merger Agreement, at the Effective Time, each option to acquire Shares under the Issuer's equity plans that was outstanding as of immediately prior to the Effective Time ceased to represent a right to acquire Shares of the Issuer, and was converted into an option to acquire shares of Topco Common Stock and assumed by Topco on the same terms and conditions (including applicable vesting and exercisability conditions) as were applicable to such option immediately prior to the Effective Time."},{"field":"derivative.underlying","element":"underlyingSecurityTitle","label":"F1","text":"The Ordinary Shares may be represented by American Depositary Shares (\"ADSs\" and together with the Ordinary Shares, the \"Shares\"), each of which currently represents one Ordinary Share."}],"balance_after":0,"derivative":{"exercise_price":1,"expiration_date":"2035-06-10","underlying":"Ordinary Shares","underlying_shares":20174},"source":{"system":"sec-edgar","filing":"0001104659-26-106342","document":"tm2625057-7_4seq1.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":6,"url":"https://www.sec.gov/Archives/edgar/data/1852070/000110465926106342/tm2625057-7_4seq1.xml","form_type":"4"}},{"id":4613368,"issuer":{"id":9597,"kind":"organization","name":"Barinthus Biotherapeutics plc.","symbol":"BRNS"},"owners":[{"id":78630,"kind":"person","name":"Scheeren Joseph","position":1,"cik":"0001852070","reported_name":"Scheeren Joseph","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Share Option (Right to Buy)","published_at":"2026-09-09T20:20:33.000Z","date":"2026-09-09","kind":"disposition_to_issuer","planned":false,"acquired":false,"shares":19516,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F2","text":"This Form 4 reports securities transacted in connection with the Agreement and Plan of Merger, dated September 29, 2025, as amended (the \"Merger Agreement\") by and among the Issuer, Beacon Topco, Inc. (\"Topco\"), a Delaware corporation and a direct wholly owned subsidiary of the Issuer, Cdog Merger Sub, Inc., a Delaware corporation and a direct wholly owned subsidiary of Topco, and Clywedog Therapeutics, Inc., a Delaware corporation. On September 9, 2026 (the \"Effective Time\"), in connection with the effectiveness of the scheme of arrangement under Part 26 of the United Kingdom Companies Act 2006 (the \"Scheme\") contemplated by the Merger Agreement, Topco acquired the entire issued share capital of the Issuer, resulting in the Issuer becoming a direct wholly owned subsidiary of Topco."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F4","text":"Pursuant to the Merger Agreement, at the Effective Time, each option to acquire Shares under the Issuer's equity plans that was outstanding as of immediately prior to the Effective Time ceased to represent a right to acquire Shares of the Issuer, and was converted into an option to acquire shares of Topco Common Stock and assumed by Topco on the same terms and conditions (including applicable vesting and exercisability conditions) as were applicable to such option immediately prior to the Effective Time."},{"field":"derivative.underlying","element":"underlyingSecurityTitle","label":"F1","text":"The Ordinary Shares may be represented by American Depositary Shares (\"ADSs\" and together with the Ordinary Shares, the \"Shares\"), each of which currently represents one Ordinary Share."}],"balance_after":0,"derivative":{"exercise_price":2.34,"expiration_date":"2034-05-10","underlying":"Ordinary Shares","underlying_shares":19516},"source":{"system":"sec-edgar","filing":"0001104659-26-106342","document":"tm2625057-7_4seq1.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":5,"url":"https://www.sec.gov/Archives/edgar/data/1852070/000110465926106342/tm2625057-7_4seq1.xml","form_type":"4"}},{"id":4613367,"issuer":{"id":9597,"kind":"organization","name":"Barinthus Biotherapeutics plc.","symbol":"BRNS"},"owners":[{"id":78630,"kind":"person","name":"Scheeren Joseph","position":1,"cik":"0001852070","reported_name":"Scheeren Joseph","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Share Option (Right to Buy)","published_at":"2026-09-09T20:20:33.000Z","date":"2026-09-09","kind":"disposition_to_issuer","planned":false,"acquired":false,"shares":19197,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F2","text":"This Form 4 reports securities transacted in connection with the Agreement and Plan of Merger, dated September 29, 2025, as amended (the \"Merger Agreement\") by and among the Issuer, Beacon Topco, Inc. (\"Topco\"), a Delaware corporation and a direct wholly owned subsidiary of the Issuer, Cdog Merger Sub, Inc., a Delaware corporation and a direct wholly owned subsidiary of Topco, and Clywedog Therapeutics, Inc., a Delaware corporation. On September 9, 2026 (the \"Effective Time\"), in connection with the effectiveness of the scheme of arrangement under Part 26 of the United Kingdom Companies Act 2006 (the \"Scheme\") contemplated by the Merger Agreement, Topco acquired the entire issued share capital of the Issuer, resulting in the Issuer becoming a direct wholly owned subsidiary of Topco."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F4","text":"Pursuant to the Merger Agreement, at the Effective Time, each option to acquire Shares under the Issuer's equity plans that was outstanding as of immediately prior to the Effective Time ceased to represent a right to acquire Shares of the Issuer, and was converted into an option to acquire shares of Topco Common Stock and assumed by Topco on the same terms and conditions (including applicable vesting and exercisability conditions) as were applicable to such option immediately prior to the Effective Time."},{"field":"derivative.underlying","element":"underlyingSecurityTitle","label":"F1","text":"The Ordinary Shares may be represented by American Depositary Shares (\"ADSs\" and together with the Ordinary Shares, the \"Shares\"), each of which currently represents one Ordinary Share."}],"balance_after":0,"derivative":{"exercise_price":2.27,"expiration_date":"2033-05-11","underlying":"Ordinary Shares","underlying_shares":19197},"source":{"system":"sec-edgar","filing":"0001104659-26-106342","document":"tm2625057-7_4seq1.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":4,"url":"https://www.sec.gov/Archives/edgar/data/1852070/000110465926106342/tm2625057-7_4seq1.xml","form_type":"4"}},{"id":4613366,"issuer":{"id":9597,"kind":"organization","name":"Barinthus Biotherapeutics plc.","symbol":"BRNS"},"owners":[{"id":78630,"kind":"person","name":"Scheeren Joseph","position":1,"cik":"0001852070","reported_name":"Scheeren Joseph","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Share Option (Right to Buy)","published_at":"2026-09-09T20:20:33.000Z","date":"2026-09-09","kind":"disposition_to_issuer","planned":false,"acquired":false,"shares":18604,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F2","text":"This Form 4 reports securities transacted in connection with the Agreement and Plan of Merger, dated September 29, 2025, as amended (the \"Merger Agreement\") by and among the Issuer, Beacon Topco, Inc. (\"Topco\"), a Delaware corporation and a direct wholly owned subsidiary of the Issuer, Cdog Merger Sub, Inc., a Delaware corporation and a direct wholly owned subsidiary of Topco, and Clywedog Therapeutics, Inc., a Delaware corporation. On September 9, 2026 (the \"Effective Time\"), in connection with the effectiveness of the scheme of arrangement under Part 26 of the United Kingdom Companies Act 2006 (the \"Scheme\") contemplated by the Merger Agreement, Topco acquired the entire issued share capital of the Issuer, resulting in the Issuer becoming a direct wholly owned subsidiary of Topco."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F4","text":"Pursuant to the Merger Agreement, at the Effective Time, each option to acquire Shares under the Issuer's equity plans that was outstanding as of immediately prior to the Effective Time ceased to represent a right to acquire Shares of the Issuer, and was converted into an option to acquire shares of Topco Common Stock and assumed by Topco on the same terms and conditions (including applicable vesting and exercisability conditions) as were applicable to such option immediately prior to the Effective Time."},{"field":"derivative.underlying","element":"underlyingSecurityTitle","label":"F1","text":"The Ordinary Shares may be represented by American Depositary Shares (\"ADSs\" and together with the Ordinary Shares, the \"Shares\"), each of which currently represents one Ordinary Share."}],"balance_after":0,"derivative":{"exercise_price":4.27,"expiration_date":"2032-06-15","underlying":"Ordinary Shares","underlying_shares":18604},"source":{"system":"sec-edgar","filing":"0001104659-26-106342","document":"tm2625057-7_4seq1.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":3,"url":"https://www.sec.gov/Archives/edgar/data/1852070/000110465926106342/tm2625057-7_4seq1.xml","form_type":"4"}},{"id":4613365,"issuer":{"id":9597,"kind":"organization","name":"Barinthus Biotherapeutics plc.","symbol":"BRNS"},"owners":[{"id":78630,"kind":"person","name":"Scheeren Joseph","position":1,"cik":"0001852070","reported_name":"Scheeren Joseph","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Share Option (Right to Buy)","published_at":"2026-09-09T20:20:33.000Z","date":"2026-09-09","kind":"disposition_to_issuer","planned":false,"acquired":false,"shares":34328,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F2","text":"This Form 4 reports securities transacted in connection with the Agreement and Plan of Merger, dated September 29, 2025, as amended (the \"Merger Agreement\") by and among the Issuer, Beacon Topco, Inc. (\"Topco\"), a Delaware corporation and a direct wholly owned subsidiary of the Issuer, Cdog Merger Sub, Inc., a Delaware corporation and a direct wholly owned subsidiary of Topco, and Clywedog Therapeutics, Inc., a Delaware corporation. On September 9, 2026 (the \"Effective Time\"), in connection with the effectiveness of the scheme of arrangement under Part 26 of the United Kingdom Companies Act 2006 (the \"Scheme\") contemplated by the Merger Agreement, Topco acquired the entire issued share capital of the Issuer, resulting in the Issuer becoming a direct wholly owned subsidiary of Topco."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F4","text":"Pursuant to the Merger Agreement, at the Effective Time, each option to acquire Shares under the Issuer's equity plans that was outstanding as of immediately prior to the Effective Time ceased to represent a right to acquire Shares of the Issuer, and was converted into an option to acquire shares of Topco Common Stock and assumed by Topco on the same terms and conditions (including applicable vesting and exercisability conditions) as were applicable to such option immediately prior to the Effective Time."},{"field":"derivative.underlying","element":"underlyingSecurityTitle","label":"F1","text":"The Ordinary Shares may be represented by American Depositary Shares (\"ADSs\" and together with the Ordinary Shares, the \"Shares\"), each of which currently represents one Ordinary Share."}],"balance_after":0,"derivative":{"exercise_price":17,"expiration_date":"2031-05-01","underlying":"Ordinary Shares","underlying_shares":34328},"source":{"system":"sec-edgar","filing":"0001104659-26-106342","document":"tm2625057-7_4seq1.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1852070/000110465926106342/tm2625057-7_4seq1.xml","form_type":"4"}},{"id":4613364,"issuer":{"id":9597,"kind":"organization","name":"Barinthus Biotherapeutics plc.","symbol":"BRNS"},"owners":[{"id":78630,"kind":"person","name":"Scheeren Joseph","position":1,"cik":"0001852070","reported_name":"Scheeren Joseph","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Ordinary Shares","published_at":"2026-09-09T20:20:33.000Z","date":"2026-09-09","kind":"disposition_to_issuer","planned":false,"acquired":false,"shares":23000,"ownership":{"direct":true},"footnotes":[{"field":"security","element":"securityTitle","label":"F1","text":"The Ordinary Shares may be represented by American Depositary Shares (\"ADSs\" and together with the Ordinary Shares, the \"Shares\"), each of which currently represents one Ordinary Share."},{"field":"kind","element":"transactionCoding","label":"F2","text":"This Form 4 reports securities transacted in connection with the Agreement and Plan of Merger, dated September 29, 2025, as amended (the \"Merger Agreement\") by and among the Issuer, Beacon Topco, Inc. (\"Topco\"), a Delaware corporation and a direct wholly owned subsidiary of the Issuer, Cdog Merger Sub, Inc., a Delaware corporation and a direct wholly owned subsidiary of Topco, and Clywedog Therapeutics, Inc., a Delaware corporation. On September 9, 2026 (the \"Effective Time\"), in connection with the effectiveness of the scheme of arrangement under Part 26 of the United Kingdom Companies Act 2006 (the \"Scheme\") contemplated by the Merger Agreement, Topco acquired the entire issued share capital of the Issuer, resulting in the Issuer becoming a direct wholly owned subsidiary of Topco."},{"field":"shares","element":"transactionShares","label":"F3","text":"Pursuant to the Merger Agreement and in connection with the effectiveness of the Scheme, at the Effective Time, each Share of the Issuer was converted into the right to receive 0.111 shares of common stock, $0.0001 par value per share, of Topco (the \"Topco Common Stock\")."},{"field":"price","element":"transactionPricePerShare","label":"F3","text":"Pursuant to the Merger Agreement and in connection with the effectiveness of the Scheme, at the Effective Time, each Share of the Issuer was converted into the right to receive 0.111 shares of common stock, $0.0001 par value per share, of Topco (the \"Topco Common Stock\")."}],"balance_after":0,"source":{"system":"sec-edgar","filing":"0001104659-26-106342","document":"tm2625057-7_4seq1.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1852070/000110465926106342/tm2625057-7_4seq1.xml","form_type":"4"}},{"id":4613363,"issuer":{"id":9597,"kind":"organization","name":"Barinthus Biotherapeutics plc.","symbol":"BRNS"},"owners":[{"id":34812,"kind":"person","name":"Phillips Anne M.","position":1,"cik":"0001627680","reported_name":"Phillips Anne M.","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Share Option (Right to Buy)","published_at":"2026-09-09T20:20:06.000Z","date":"2026-09-09","kind":"disposition_to_issuer","planned":false,"acquired":false,"shares":20174,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F2","text":"This Form 4 reports securities transacted in connection with the Agreement and Plan of Merger, dated September 29, 2025, as amended (the \"Merger Agreement\") by and among the Issuer, Beacon Topco, Inc. (\"Topco\"), a Delaware corporation and a direct wholly owned subsidiary of the Issuer, Cdog Merger Sub, Inc., a Delaware corporation and a direct wholly owned subsidiary of Topco, and Clywedog Therapeutics, Inc., a Delaware corporation. On September 9, 2026 (the \"Effective Time\"), in connection with the effectiveness of the scheme of arrangement under Part 26 of the United Kingdom Companies Act 2006 (the \"Scheme\") contemplated by the Merger Agreement, Topco acquired the entire issued share capital of the Issuer, resulting in the Issuer becoming a direct wholly owned subsidiary of Topco."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F4","text":"Pursuant to the Merger Agreement, at the Effective Time, each option to acquire Shares under the Issuer's equity plans that was outstanding as of immediately prior to the Effective Time ceased to represent a right to acquire Shares of the Issuer, and was converted into an option to acquire shares of Topco Common Stock and assumed by Topco on the same terms and conditions (including applicable vesting and exercisability conditions) as were applicable to such option immediately prior to the Effective Time."},{"field":"derivative.underlying","element":"underlyingSecurityTitle","label":"F1","text":"The Ordinary Shares may be represented by American Depositary Shares (\"ADSs\" and together with the Ordinary Shares, the \"Shares\"), each of which currently represents one Ordinary Share."}],"balance_after":0,"derivative":{"exercise_price":1,"expiration_date":"2035-06-10","underlying":"Ordinary Shares","underlying_shares":20174},"source":{"system":"sec-edgar","filing":"0001104659-26-106341","document":"tm2625057-6_4seq1.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":6,"url":"https://www.sec.gov/Archives/edgar/data/1828185/000110465926106341/tm2625057-6_4seq1.xml","form_type":"4"}},{"id":4613362,"issuer":{"id":9597,"kind":"organization","name":"Barinthus Biotherapeutics plc.","symbol":"BRNS"},"owners":[{"id":34812,"kind":"person","name":"Phillips Anne M.","position":1,"cik":"0001627680","reported_name":"Phillips Anne M.","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Share Option (Right to Buy)","published_at":"2026-09-09T20:20:06.000Z","date":"2026-09-09","kind":"disposition_to_issuer","planned":false,"acquired":false,"shares":19516,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F2","text":"This Form 4 reports securities transacted in connection with the Agreement and Plan of Merger, dated September 29, 2025, as amended (the \"Merger Agreement\") by and among the Issuer, Beacon Topco, Inc. (\"Topco\"), a Delaware corporation and a direct wholly owned subsidiary of the Issuer, Cdog Merger Sub, Inc., a Delaware corporation and a direct wholly owned subsidiary of Topco, and Clywedog Therapeutics, Inc., a Delaware corporation. On September 9, 2026 (the \"Effective Time\"), in connection with the effectiveness of the scheme of arrangement under Part 26 of the United Kingdom Companies Act 2006 (the \"Scheme\") contemplated by the Merger Agreement, Topco acquired the entire issued share capital of the Issuer, resulting in the Issuer becoming a direct wholly owned subsidiary of Topco."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F4","text":"Pursuant to the Merger Agreement, at the Effective Time, each option to acquire Shares under the Issuer's equity plans that was outstanding as of immediately prior to the Effective Time ceased to represent a right to acquire Shares of the Issuer, and was converted into an option to acquire shares of Topco Common Stock and assumed by Topco on the same terms and conditions (including applicable vesting and exercisability conditions) as were applicable to such option immediately prior to the Effective Time."},{"field":"derivative.underlying","element":"underlyingSecurityTitle","label":"F1","text":"The Ordinary Shares may be represented by American Depositary Shares (\"ADSs\" and together with the Ordinary Shares, the \"Shares\"), each of which currently represents one Ordinary Share."}],"balance_after":0,"derivative":{"exercise_price":2.34,"expiration_date":"2034-05-10","underlying":"Ordinary Shares","underlying_shares":19516},"source":{"system":"sec-edgar","filing":"0001104659-26-106341","document":"tm2625057-6_4seq1.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":5,"url":"https://www.sec.gov/Archives/edgar/data/1828185/000110465926106341/tm2625057-6_4seq1.xml","form_type":"4"}},{"id":4613361,"issuer":{"id":9597,"kind":"organization","name":"Barinthus Biotherapeutics plc.","symbol":"BRNS"},"owners":[{"id":34812,"kind":"person","name":"Phillips Anne M.","position":1,"cik":"0001627680","reported_name":"Phillips Anne M.","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Share Option (Right to Buy)","published_at":"2026-09-09T20:20:06.000Z","date":"2026-09-09","kind":"disposition_to_issuer","planned":false,"acquired":false,"shares":19197,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F2","text":"This Form 4 reports securities transacted in connection with the Agreement and Plan of Merger, dated September 29, 2025, as amended (the \"Merger Agreement\") by and among the Issuer, Beacon Topco, Inc. (\"Topco\"), a Delaware corporation and a direct wholly owned subsidiary of the Issuer, Cdog Merger Sub, Inc., a Delaware corporation and a direct wholly owned subsidiary of Topco, and Clywedog Therapeutics, Inc., a Delaware corporation. On September 9, 2026 (the \"Effective Time\"), in connection with the effectiveness of the scheme of arrangement under Part 26 of the United Kingdom Companies Act 2006 (the \"Scheme\") contemplated by the Merger Agreement, Topco acquired the entire issued share capital of the Issuer, resulting in the Issuer becoming a direct wholly owned subsidiary of Topco."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F4","text":"Pursuant to the Merger Agreement, at the Effective Time, each option to acquire Shares under the Issuer's equity plans that was outstanding as of immediately prior to the Effective Time ceased to represent a right to acquire Shares of the Issuer, and was converted into an option to acquire shares of Topco Common Stock and assumed by Topco on the same terms and conditions (including applicable vesting and exercisability conditions) as were applicable to such option immediately prior to the Effective Time."},{"field":"derivative.underlying","element":"underlyingSecurityTitle","label":"F1","text":"The Ordinary Shares may be represented by American Depositary Shares (\"ADSs\" and together with the Ordinary Shares, the \"Shares\"), each of which currently represents one Ordinary Share."}],"balance_after":0,"derivative":{"exercise_price":2.27,"expiration_date":"2033-05-11","underlying":"Ordinary Shares","underlying_shares":19197},"source":{"system":"sec-edgar","filing":"0001104659-26-106341","document":"tm2625057-6_4seq1.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":4,"url":"https://www.sec.gov/Archives/edgar/data/1828185/000110465926106341/tm2625057-6_4seq1.xml","form_type":"4"}},{"id":4613360,"issuer":{"id":9597,"kind":"organization","name":"Barinthus Biotherapeutics plc.","symbol":"BRNS"},"owners":[{"id":34812,"kind":"person","name":"Phillips Anne M.","position":1,"cik":"0001627680","reported_name":"Phillips Anne M.","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Share Option (Right to Buy)","published_at":"2026-09-09T20:20:06.000Z","date":"2026-09-09","kind":"disposition_to_issuer","planned":false,"acquired":false,"shares":18604,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F2","text":"This Form 4 reports securities transacted in connection with the Agreement and Plan of Merger, dated September 29, 2025, as amended (the \"Merger Agreement\") by and among the Issuer, Beacon Topco, Inc. (\"Topco\"), a Delaware corporation and a direct wholly owned subsidiary of the Issuer, Cdog Merger Sub, Inc., a Delaware corporation and a direct wholly owned subsidiary of Topco, and Clywedog Therapeutics, Inc., a Delaware corporation. On September 9, 2026 (the \"Effective Time\"), in connection with the effectiveness of the scheme of arrangement under Part 26 of the United Kingdom Companies Act 2006 (the \"Scheme\") contemplated by the Merger Agreement, Topco acquired the entire issued share capital of the Issuer, resulting in the Issuer becoming a direct wholly owned subsidiary of Topco."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F4","text":"Pursuant to the Merger Agreement, at the Effective Time, each option to acquire Shares under the Issuer's equity plans that was outstanding as of immediately prior to the Effective Time ceased to represent a right to acquire Shares of the Issuer, and was converted into an option to acquire shares of Topco Common Stock and assumed by Topco on the same terms and conditions (including applicable vesting and exercisability conditions) as were applicable to such option immediately prior to the Effective Time."},{"field":"derivative.underlying","element":"underlyingSecurityTitle","label":"F1","text":"The Ordinary Shares may be represented by American Depositary Shares (\"ADSs\" and together with the Ordinary Shares, the \"Shares\"), each of which currently represents one Ordinary Share."}],"balance_after":0,"derivative":{"exercise_price":4.27,"expiration_date":"2032-06-15","underlying":"Ordinary Shares","underlying_shares":18604},"source":{"system":"sec-edgar","filing":"0001104659-26-106341","document":"tm2625057-6_4seq1.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":3,"url":"https://www.sec.gov/Archives/edgar/data/1828185/000110465926106341/tm2625057-6_4seq1.xml","form_type":"4"}},{"id":4613359,"issuer":{"id":9597,"kind":"organization","name":"Barinthus Biotherapeutics plc.","symbol":"BRNS"},"owners":[{"id":34812,"kind":"person","name":"Phillips Anne M.","position":1,"cik":"0001627680","reported_name":"Phillips Anne M.","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Share Option (Right to Buy)","published_at":"2026-09-09T20:20:06.000Z","date":"2026-09-09","kind":"disposition_to_issuer","planned":false,"acquired":false,"shares":34328,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F2","text":"This Form 4 reports securities transacted in connection with the Agreement and Plan of Merger, dated September 29, 2025, as amended (the \"Merger Agreement\") by and among the Issuer, Beacon Topco, Inc. (\"Topco\"), a Delaware corporation and a direct wholly owned subsidiary of the Issuer, Cdog Merger Sub, Inc., a Delaware corporation and a direct wholly owned subsidiary of Topco, and Clywedog Therapeutics, Inc., a Delaware corporation. On September 9, 2026 (the \"Effective Time\"), in connection with the effectiveness of the scheme of arrangement under Part 26 of the United Kingdom Companies Act 2006 (the \"Scheme\") contemplated by the Merger Agreement, Topco acquired the entire issued share capital of the Issuer, resulting in the Issuer becoming a direct wholly owned subsidiary of Topco."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F4","text":"Pursuant to the Merger Agreement, at the Effective Time, each option to acquire Shares under the Issuer's equity plans that was outstanding as of immediately prior to the Effective Time ceased to represent a right to acquire Shares of the Issuer, and was converted into an option to acquire shares of Topco Common Stock and assumed by Topco on the same terms and conditions (including applicable vesting and exercisability conditions) as were applicable to such option immediately prior to the Effective Time."},{"field":"derivative.underlying","element":"underlyingSecurityTitle","label":"F1","text":"The Ordinary Shares may be represented by American Depositary Shares (\"ADSs\" and together with the Ordinary Shares, the \"Shares\"), each of which currently represents one Ordinary Share."}],"balance_after":0,"derivative":{"exercise_price":17,"expiration_date":"2031-05-01","underlying":"Ordinary Shares","underlying_shares":34328},"source":{"system":"sec-edgar","filing":"0001104659-26-106341","document":"tm2625057-6_4seq1.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1828185/000110465926106341/tm2625057-6_4seq1.xml","form_type":"4"}},{"id":4613358,"issuer":{"id":9597,"kind":"organization","name":"Barinthus Biotherapeutics plc.","symbol":"BRNS"},"owners":[{"id":34812,"kind":"person","name":"Phillips Anne M.","position":1,"cik":"0001627680","reported_name":"Phillips Anne M.","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Ordinary Shares","published_at":"2026-09-09T20:20:06.000Z","date":"2026-09-09","kind":"disposition_to_issuer","planned":false,"acquired":false,"shares":3000,"ownership":{"direct":true},"footnotes":[{"field":"security","element":"securityTitle","label":"F1","text":"The Ordinary Shares may be represented by American Depositary Shares (\"ADSs\" and together with the Ordinary Shares, the \"Shares\"), each of which currently represents one Ordinary Share."},{"field":"kind","element":"transactionCoding","label":"F2","text":"This Form 4 reports securities transacted in connection with the Agreement and Plan of Merger, dated September 29, 2025, as amended (the \"Merger Agreement\") by and among the Issuer, Beacon Topco, Inc. (\"Topco\"), a Delaware corporation and a direct wholly owned subsidiary of the Issuer, Cdog Merger Sub, Inc., a Delaware corporation and a direct wholly owned subsidiary of Topco, and Clywedog Therapeutics, Inc., a Delaware corporation. On September 9, 2026 (the \"Effective Time\"), in connection with the effectiveness of the scheme of arrangement under Part 26 of the United Kingdom Companies Act 2006 (the \"Scheme\") contemplated by the Merger Agreement, Topco acquired the entire issued share capital of the Issuer, resulting in the Issuer becoming a direct wholly owned subsidiary of Topco."},{"field":"shares","element":"transactionShares","label":"F3","text":"Pursuant to the Merger Agreement and in connection with the effectiveness of the Scheme, at the Effective Time, each Share of the Issuer was converted into the right to receive 0.111 shares of common stock, $0.0001 par value per share, of Topco (the \"Topco Common Stock\")."},{"field":"price","element":"transactionPricePerShare","label":"F3","text":"Pursuant to the Merger Agreement and in connection with the effectiveness of the Scheme, at the Effective Time, each Share of the Issuer was converted into the right to receive 0.111 shares of common stock, $0.0001 par value per share, of Topco (the \"Topco Common Stock\")."}],"balance_after":0,"source":{"system":"sec-edgar","filing":"0001104659-26-106341","document":"tm2625057-6_4seq1.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1828185/000110465926106341/tm2625057-6_4seq1.xml","form_type":"4"}},{"id":4613357,"issuer":{"id":9597,"kind":"organization","name":"Barinthus Biotherapeutics plc.","symbol":"BRNS"},"owners":[{"id":78628,"kind":"person","name":"Morgon Pierre A.","position":1,"cik":"0001851636","reported_name":"Morgon Pierre A.","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Share Option (Right to Buy)","published_at":"2026-09-09T20:19:38.000Z","date":"2026-09-09","kind":"disposition_to_issuer","planned":false,"acquired":false,"shares":20174,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F2","text":"This Form 4 reports securities transacted in connection with the Agreement and Plan of Merger, dated September 29, 2025, as amended (the \"Merger Agreement\") by and among the Issuer, Beacon Topco, Inc. (\"Topco\"), a Delaware corporation and a direct wholly owned subsidiary of the Issuer, Cdog Merger Sub, Inc., a Delaware corporation and a direct wholly owned subsidiary of Topco, and Clywedog Therapeutics, Inc., a Delaware corporation. On September 9, 2026 (the \"Effective Time\"), in connection with the effectiveness of the scheme of arrangement under Part 26 of the United Kingdom Companies Act 2006 (the \"Scheme\") contemplated by the Merger Agreement, Topco acquired the entire issued share capital of the Issuer, resulting in the Issuer becoming a direct wholly owned subsidiary of Topco."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F4","text":"Pursuant to the Merger Agreement, at the Effective Time, each option to acquire Shares under the Issuer's equity plans that was outstanding as of immediately prior to the Effective Time ceased to represent a right to acquire Shares of the Issuer, and was converted into an option to acquire shares of Topco Common Stock and assumed by Topco on the same terms and conditions (including applicable vesting and exercisability conditions) as were applicable to such option immediately prior to the Effective Time."},{"field":"derivative.underlying","element":"underlyingSecurityTitle","label":"F1","text":"The Ordinary Shares may be represented by American Depositary Shares (\"ADSs\" and together with the Ordinary Shares, the \"Shares\"), each of which currently represents one Ordinary Share."}],"balance_after":0,"derivative":{"exercise_price":1,"expiration_date":"2035-06-10","underlying":"Ordinary Shares","underlying_shares":20174},"source":{"system":"sec-edgar","filing":"0001104659-26-106340","document":"tm2625057-5_4seq1.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":7,"url":"https://www.sec.gov/Archives/edgar/data/1851636/000110465926106340/tm2625057-5_4seq1.xml","form_type":"4"}},{"id":4613356,"issuer":{"id":9597,"kind":"organization","name":"Barinthus Biotherapeutics plc.","symbol":"BRNS"},"owners":[{"id":78628,"kind":"person","name":"Morgon Pierre A.","position":1,"cik":"0001851636","reported_name":"Morgon Pierre A.","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Share Option (Right to Buy)","published_at":"2026-09-09T20:19:38.000Z","date":"2026-09-09","kind":"disposition_to_issuer","planned":false,"acquired":false,"shares":19516,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F2","text":"This Form 4 reports securities transacted in connection with the Agreement and Plan of Merger, dated September 29, 2025, as amended (the \"Merger Agreement\") by and among the Issuer, Beacon Topco, Inc. (\"Topco\"), a Delaware corporation and a direct wholly owned subsidiary of the Issuer, Cdog Merger Sub, Inc., a Delaware corporation and a direct wholly owned subsidiary of Topco, and Clywedog Therapeutics, Inc., a Delaware corporation. On September 9, 2026 (the \"Effective Time\"), in connection with the effectiveness of the scheme of arrangement under Part 26 of the United Kingdom Companies Act 2006 (the \"Scheme\") contemplated by the Merger Agreement, Topco acquired the entire issued share capital of the Issuer, resulting in the Issuer becoming a direct wholly owned subsidiary of Topco."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F4","text":"Pursuant to the Merger Agreement, at the Effective Time, each option to acquire Shares under the Issuer's equity plans that was outstanding as of immediately prior to the Effective Time ceased to represent a right to acquire Shares of the Issuer, and was converted into an option to acquire shares of Topco Common Stock and assumed by Topco on the same terms and conditions (including applicable vesting and exercisability conditions) as were applicable to such option immediately prior to the Effective Time."},{"field":"derivative.underlying","element":"underlyingSecurityTitle","label":"F1","text":"The Ordinary Shares may be represented by American Depositary Shares (\"ADSs\" and together with the Ordinary Shares, the \"Shares\"), each of which currently represents one Ordinary Share."}],"balance_after":0,"derivative":{"exercise_price":2.34,"expiration_date":"2034-05-10","underlying":"Ordinary Shares","underlying_shares":19516},"source":{"system":"sec-edgar","filing":"0001104659-26-106340","document":"tm2625057-5_4seq1.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":6,"url":"https://www.sec.gov/Archives/edgar/data/1851636/000110465926106340/tm2625057-5_4seq1.xml","form_type":"4"}},{"id":4613355,"issuer":{"id":9597,"kind":"organization","name":"Barinthus Biotherapeutics plc.","symbol":"BRNS"},"owners":[{"id":78628,"kind":"person","name":"Morgon Pierre A.","position":1,"cik":"0001851636","reported_name":"Morgon Pierre A.","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Share Option (Right to Buy)","published_at":"2026-09-09T20:19:38.000Z","date":"2026-09-09","kind":"disposition_to_issuer","planned":false,"acquired":false,"shares":19197,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F2","text":"This Form 4 reports securities transacted in connection with the Agreement and Plan of Merger, dated September 29, 2025, as amended (the \"Merger Agreement\") by and among the Issuer, Beacon Topco, Inc. (\"Topco\"), a Delaware corporation and a direct wholly owned subsidiary of the Issuer, Cdog Merger Sub, Inc., a Delaware corporation and a direct wholly owned subsidiary of Topco, and Clywedog Therapeutics, Inc., a Delaware corporation. On September 9, 2026 (the \"Effective Time\"), in connection with the effectiveness of the scheme of arrangement under Part 26 of the United Kingdom Companies Act 2006 (the \"Scheme\") contemplated by the Merger Agreement, Topco acquired the entire issued share capital of the Issuer, resulting in the Issuer becoming a direct wholly owned subsidiary of Topco."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F4","text":"Pursuant to the Merger Agreement, at the Effective Time, each option to acquire Shares under the Issuer's equity plans that was outstanding as of immediately prior to the Effective Time ceased to represent a right to acquire Shares of the Issuer, and was converted into an option to acquire shares of Topco Common Stock and assumed by Topco on the same terms and conditions (including applicable vesting and exercisability conditions) as were applicable to such option immediately prior to the Effective Time."},{"field":"derivative.underlying","element":"underlyingSecurityTitle","label":"F1","text":"The Ordinary Shares may be represented by American Depositary Shares (\"ADSs\" and together with the Ordinary Shares, the \"Shares\"), each of which currently represents one Ordinary Share."}],"balance_after":0,"derivative":{"exercise_price":2.27,"expiration_date":"2033-05-11","underlying":"Ordinary Shares","underlying_shares":19197},"source":{"system":"sec-edgar","filing":"0001104659-26-106340","document":"tm2625057-5_4seq1.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":5,"url":"https://www.sec.gov/Archives/edgar/data/1851636/000110465926106340/tm2625057-5_4seq1.xml","form_type":"4"}},{"id":4613354,"issuer":{"id":9597,"kind":"organization","name":"Barinthus Biotherapeutics plc.","symbol":"BRNS"},"owners":[{"id":78628,"kind":"person","name":"Morgon Pierre A.","position":1,"cik":"0001851636","reported_name":"Morgon Pierre A.","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Share Option (Right to Buy)","published_at":"2026-09-09T20:19:38.000Z","date":"2026-09-09","kind":"disposition_to_issuer","planned":false,"acquired":false,"shares":18604,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F2","text":"This Form 4 reports securities transacted in connection with the Agreement and Plan of Merger, dated September 29, 2025, as amended (the \"Merger Agreement\") by and among the Issuer, Beacon Topco, Inc. (\"Topco\"), a Delaware corporation and a direct wholly owned subsidiary of the Issuer, Cdog Merger Sub, Inc., a Delaware corporation and a direct wholly owned subsidiary of Topco, and Clywedog Therapeutics, Inc., a Delaware corporation. On September 9, 2026 (the \"Effective Time\"), in connection with the effectiveness of the scheme of arrangement under Part 26 of the United Kingdom Companies Act 2006 (the \"Scheme\") contemplated by the Merger Agreement, Topco acquired the entire issued share capital of the Issuer, resulting in the Issuer becoming a direct wholly owned subsidiary of Topco."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F4","text":"Pursuant to the Merger Agreement, at the Effective Time, each option to acquire Shares under the Issuer's equity plans that was outstanding as of immediately prior to the Effective Time ceased to represent a right to acquire Shares of the Issuer, and was converted into an option to acquire shares of Topco Common Stock and assumed by Topco on the same terms and conditions (including applicable vesting and exercisability conditions) as were applicable to such option immediately prior to the Effective Time."},{"field":"derivative.underlying","element":"underlyingSecurityTitle","label":"F1","text":"The Ordinary Shares may be represented by American Depositary Shares (\"ADSs\" and together with the Ordinary Shares, the \"Shares\"), each of which currently represents one Ordinary Share."}],"balance_after":0,"derivative":{"exercise_price":4.27,"expiration_date":"2032-06-15","underlying":"Ordinary Shares","underlying_shares":18604},"source":{"system":"sec-edgar","filing":"0001104659-26-106340","document":"tm2625057-5_4seq1.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":4,"url":"https://www.sec.gov/Archives/edgar/data/1851636/000110465926106340/tm2625057-5_4seq1.xml","form_type":"4"}},{"id":4613353,"issuer":{"id":9597,"kind":"organization","name":"Barinthus Biotherapeutics plc.","symbol":"BRNS"},"owners":[{"id":78628,"kind":"person","name":"Morgon Pierre A.","position":1,"cik":"0001851636","reported_name":"Morgon Pierre A.","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Share Option (Right to Buy)","published_at":"2026-09-09T20:19:38.000Z","date":"2026-09-09","kind":"disposition_to_issuer","planned":false,"acquired":false,"shares":34328,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F2","text":"This Form 4 reports securities transacted in connection with the Agreement and Plan of Merger, dated September 29, 2025, as amended (the \"Merger Agreement\") by and among the Issuer, Beacon Topco, Inc. (\"Topco\"), a Delaware corporation and a direct wholly owned subsidiary of the Issuer, Cdog Merger Sub, Inc., a Delaware corporation and a direct wholly owned subsidiary of Topco, and Clywedog Therapeutics, Inc., a Delaware corporation. On September 9, 2026 (the \"Effective Time\"), in connection with the effectiveness of the scheme of arrangement under Part 26 of the United Kingdom Companies Act 2006 (the \"Scheme\") contemplated by the Merger Agreement, Topco acquired the entire issued share capital of the Issuer, resulting in the Issuer becoming a direct wholly owned subsidiary of Topco."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F4","text":"Pursuant to the Merger Agreement, at the Effective Time, each option to acquire Shares under the Issuer's equity plans that was outstanding as of immediately prior to the Effective Time ceased to represent a right to acquire Shares of the Issuer, and was converted into an option to acquire shares of Topco Common Stock and assumed by Topco on the same terms and conditions (including applicable vesting and exercisability conditions) as were applicable to such option immediately prior to the Effective Time."},{"field":"derivative.underlying","element":"underlyingSecurityTitle","label":"F1","text":"The Ordinary Shares may be represented by American Depositary Shares (\"ADSs\" and together with the Ordinary Shares, the \"Shares\"), each of which currently represents one Ordinary Share."}],"balance_after":0,"derivative":{"exercise_price":17,"expiration_date":"2031-05-01","underlying":"Ordinary Shares","underlying_shares":34328},"source":{"system":"sec-edgar","filing":"0001104659-26-106340","document":"tm2625057-5_4seq1.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":3,"url":"https://www.sec.gov/Archives/edgar/data/1851636/000110465926106340/tm2625057-5_4seq1.xml","form_type":"4"}},{"id":4613352,"issuer":{"id":9597,"kind":"organization","name":"Barinthus Biotherapeutics plc.","symbol":"BRNS"},"owners":[{"id":78628,"kind":"person","name":"Morgon Pierre A.","position":1,"cik":"0001851636","reported_name":"Morgon Pierre A.","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Share Option (Right to Buy)","published_at":"2026-09-09T20:19:38.000Z","date":"2026-09-09","kind":"disposition_to_issuer","planned":false,"acquired":false,"shares":20394,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F2","text":"This Form 4 reports securities transacted in connection with the Agreement and Plan of Merger, dated September 29, 2025, as amended (the \"Merger Agreement\") by and among the Issuer, Beacon Topco, Inc. (\"Topco\"), a Delaware corporation and a direct wholly owned subsidiary of the Issuer, Cdog Merger Sub, Inc., a Delaware corporation and a direct wholly owned subsidiary of Topco, and Clywedog Therapeutics, Inc., a Delaware corporation. On September 9, 2026 (the \"Effective Time\"), in connection with the effectiveness of the scheme of arrangement under Part 26 of the United Kingdom Companies Act 2006 (the \"Scheme\") contemplated by the Merger Agreement, Topco acquired the entire issued share capital of the Issuer, resulting in the Issuer becoming a direct wholly owned subsidiary of Topco."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F4","text":"Pursuant to the Merger Agreement, at the Effective Time, each option to acquire Shares under the Issuer's equity plans that was outstanding as of immediately prior to the Effective Time ceased to represent a right to acquire Shares of the Issuer, and was converted into an option to acquire shares of Topco Common Stock and assumed by Topco on the same terms and conditions (including applicable vesting and exercisability conditions) as were applicable to such option immediately prior to the Effective Time."},{"field":"derivative.underlying","element":"underlyingSecurityTitle","label":"F1","text":"The Ordinary Shares may be represented by American Depositary Shares (\"ADSs\" and together with the Ordinary Shares, the \"Shares\"), each of which currently represents one Ordinary Share."}],"balance_after":0,"derivative":{"exercise_price":0.0001,"expiration_date":"2030-01-10","underlying":"Ordinary Shares","underlying_shares":20394},"source":{"system":"sec-edgar","filing":"0001104659-26-106340","document":"tm2625057-5_4seq1.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1851636/000110465926106340/tm2625057-5_4seq1.xml","form_type":"4"}},{"id":4613351,"issuer":{"id":9597,"kind":"organization","name":"Barinthus Biotherapeutics plc.","symbol":"BRNS"},"owners":[{"id":78628,"kind":"person","name":"Morgon Pierre A.","position":1,"cik":"0001851636","reported_name":"Morgon Pierre A.","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Ordinary Shares","published_at":"2026-09-09T20:19:38.000Z","date":"2026-09-09","kind":"disposition_to_issuer","planned":false,"acquired":false,"shares":10506,"ownership":{"direct":true},"footnotes":[{"field":"security","element":"securityTitle","label":"F1","text":"The Ordinary Shares may be represented by American Depositary Shares (\"ADSs\" and together with the Ordinary Shares, the \"Shares\"), each of which currently represents one Ordinary Share."},{"field":"kind","element":"transactionCoding","label":"F2","text":"This Form 4 reports securities transacted in connection with the Agreement and Plan of Merger, dated September 29, 2025, as amended (the \"Merger Agreement\") by and among the Issuer, Beacon Topco, Inc. (\"Topco\"), a Delaware corporation and a direct wholly owned subsidiary of the Issuer, Cdog Merger Sub, Inc., a Delaware corporation and a direct wholly owned subsidiary of Topco, and Clywedog Therapeutics, Inc., a Delaware corporation. On September 9, 2026 (the \"Effective Time\"), in connection with the effectiveness of the scheme of arrangement under Part 26 of the United Kingdom Companies Act 2006 (the \"Scheme\") contemplated by the Merger Agreement, Topco acquired the entire issued share capital of the Issuer, resulting in the Issuer becoming a direct wholly owned subsidiary of Topco."},{"field":"shares","element":"transactionShares","label":"F3","text":"Pursuant to the Merger Agreement and in connection with the effectiveness of the Scheme, at the Effective Time, each Share of the Issuer was converted into the right to receive 0.111 shares of common stock, $0.0001 par value per share, of Topco (the \"Topco Common Stock\")."},{"field":"price","element":"transactionPricePerShare","label":"F3","text":"Pursuant to the Merger Agreement and in connection with the effectiveness of the Scheme, at the Effective Time, each Share of the Issuer was converted into the right to receive 0.111 shares of common stock, $0.0001 par value per share, of Topco (the \"Topco Common Stock\")."}],"balance_after":0,"source":{"system":"sec-edgar","filing":"0001104659-26-106340","document":"tm2625057-5_4seq1.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1851636/000110465926106340/tm2625057-5_4seq1.xml","form_type":"4"}},{"id":4613347,"issuer":{"id":9597,"kind":"organization","name":"Barinthus Biotherapeutics plc.","symbol":"BRNS"},"owners":[{"id":83565,"kind":"person","name":"Hooftman Leon","position":1,"cik":"0002027157","reported_name":"Hooftman Leon","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Medical Officer"}}],"security":"Share Option (Right to Buy)","published_at":"2026-09-09T20:19:07.000Z","date":"2026-09-09","kind":"disposition_to_issuer","planned":false,"acquired":false,"shares":140000,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F2","text":"This Form 4 reports securities transacted in connection with the Agreement and Plan of Merger, dated September 29, 2025, as amended (the \"Merger Agreement\") by and among the Issuer, Beacon Topco, Inc. (\"Topco\"), a Delaware corporation and a direct wholly owned subsidiary of the Issuer, Cdog Merger Sub, Inc., a Delaware corporation and a direct wholly owned subsidiary of Topco, and Clywedog Therapeutics, Inc., a Delaware corporation. On September 9, 2026 (the \"Effective Time\"), in connection with the effectiveness of the scheme of arrangement under Part 26 of the United Kingdom Companies Act 2006 (the \"Scheme\") contemplated by the Merger Agreement, Topco acquired the entire issued share capital of the Issuer, resulting in the Issuer becoming a direct wholly owned subsidiary of Topco."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F4","text":"Pursuant to the Merger Agreement, at the Effective Time, each option to acquire Shares under the Issuer's equity plans that was outstanding as of immediately prior to the Effective Time ceased to represent a right to acquire Shares of the Issuer, and was converted into an option to acquire shares of Topco Common Stock and assumed by Topco on the same terms and conditions (including applicable vesting and exercisability conditions) as were applicable to such option immediately prior to the Effective Time."},{"field":"derivative.underlying","element":"underlyingSecurityTitle","label":"F1","text":"The Ordinary Shares may be represented by American Depositary Shares (\"ADSs\" and together with the Ordinary Shares, the \"Shares\"), each of which currently represents one Ordinary Share."}],"balance_after":0,"derivative":{"exercise_price":1,"expiration_date":"2035-02-03","underlying":"Ordinary Shares","underlying_shares":140000},"source":{"system":"sec-edgar","filing":"0001104659-26-106338","document":"tm2625057-4_4seq1.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":4,"url":"https://www.sec.gov/Archives/edgar/data/2027157/000110465926106338/tm2625057-4_4seq1.xml","form_type":"4"}},{"id":4613346,"issuer":{"id":9597,"kind":"organization","name":"Barinthus Biotherapeutics plc.","symbol":"BRNS"},"owners":[{"id":83565,"kind":"person","name":"Hooftman Leon","position":1,"cik":"0002027157","reported_name":"Hooftman Leon","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Medical Officer"}}],"security":"Share Option (Right to Buy)","published_at":"2026-09-09T20:19:07.000Z","date":"2026-09-09","kind":"disposition_to_issuer","planned":false,"acquired":false,"shares":195166,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F2","text":"This Form 4 reports securities transacted in connection with the Agreement and Plan of Merger, dated September 29, 2025, as amended (the \"Merger Agreement\") by and among the Issuer, Beacon Topco, Inc. (\"Topco\"), a Delaware corporation and a direct wholly owned subsidiary of the Issuer, Cdog Merger Sub, Inc., a Delaware corporation and a direct wholly owned subsidiary of Topco, and Clywedog Therapeutics, Inc., a Delaware corporation. On September 9, 2026 (the \"Effective Time\"), in connection with the effectiveness of the scheme of arrangement under Part 26 of the United Kingdom Companies Act 2006 (the \"Scheme\") contemplated by the Merger Agreement, Topco acquired the entire issued share capital of the Issuer, resulting in the Issuer becoming a direct wholly owned subsidiary of Topco."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F4","text":"Pursuant to the Merger Agreement, at the Effective Time, each option to acquire Shares under the Issuer's equity plans that was outstanding as of immediately prior to the Effective Time ceased to represent a right to acquire Shares of the Issuer, and was converted into an option to acquire shares of Topco Common Stock and assumed by Topco on the same terms and conditions (including applicable vesting and exercisability conditions) as were applicable to such option immediately prior to the Effective Time."},{"field":"derivative.underlying","element":"underlyingSecurityTitle","label":"F1","text":"The Ordinary Shares may be represented by American Depositary Shares (\"ADSs\" and together with the Ordinary Shares, the \"Shares\"), each of which currently represents one Ordinary Share."}],"balance_after":0,"derivative":{"exercise_price":2,"expiration_date":"2034-06-03","underlying":"Ordinary Shares","underlying_shares":195166},"source":{"system":"sec-edgar","filing":"0001104659-26-106338","document":"tm2625057-4_4seq1.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":3,"url":"https://www.sec.gov/Archives/edgar/data/2027157/000110465926106338/tm2625057-4_4seq1.xml","form_type":"4"}},{"id":4613345,"issuer":{"id":9597,"kind":"organization","name":"Barinthus Biotherapeutics plc.","symbol":"BRNS"},"owners":[{"id":83565,"kind":"person","name":"Hooftman Leon","position":1,"cik":"0002027157","reported_name":"Hooftman Leon","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Medical Officer"}}],"security":"Ordinary Shares","published_at":"2026-09-09T20:19:07.000Z","date":"2026-09-09","kind":"disposition_to_issuer","planned":false,"acquired":false,"shares":361530,"ownership":{"direct":true},"footnotes":[{"field":"security","element":"securityTitle","label":"F1","text":"The Ordinary Shares may be represented by American Depositary Shares (\"ADSs\" and together with the Ordinary Shares, the \"Shares\"), each of which currently represents one Ordinary Share."},{"field":"kind","element":"transactionCoding","label":"F2","text":"This Form 4 reports securities transacted in connection with the Agreement and Plan of Merger, dated September 29, 2025, as amended (the \"Merger Agreement\") by and among the Issuer, Beacon Topco, Inc. (\"Topco\"), a Delaware corporation and a direct wholly owned subsidiary of the Issuer, Cdog Merger Sub, Inc., a Delaware corporation and a direct wholly owned subsidiary of Topco, and Clywedog Therapeutics, Inc., a Delaware corporation. On September 9, 2026 (the \"Effective Time\"), in connection with the effectiveness of the scheme of arrangement under Part 26 of the United Kingdom Companies Act 2006 (the \"Scheme\") contemplated by the Merger Agreement, Topco acquired the entire issued share capital of the Issuer, resulting in the Issuer becoming a direct wholly owned subsidiary of Topco."},{"field":"shares","element":"transactionShares","label":"F3","text":"Represents restricted share units (\"RSUs\") previously granted to the Reporting Person, vesting of which was subject to completion of the transactions contemplated by the Merger Agreement. Each RSU represented the contingent right to receive one Share of the Issuer. At the Effective time, each RSU, whether or not then vested, was automatically released in consideration of the assumption of such RSU by Topco and converted into an RSU relating to the common stock, $0.0001 par value per share, of Topco (the \"Topco Common Stock\")."},{"field":"price","element":"transactionPricePerShare","label":"F3","text":"Represents restricted share units (\"RSUs\") previously granted to the Reporting Person, vesting of which was subject to completion of the transactions contemplated by the Merger Agreement. Each RSU represented the contingent right to receive one Share of the Issuer. At the Effective time, each RSU, whether or not then vested, was automatically released in consideration of the assumption of such RSU by Topco and converted into an RSU relating to the common stock, $0.0001 par value per share, of Topco (the \"Topco Common Stock\")."}],"balance_after":0,"source":{"system":"sec-edgar","filing":"0001104659-26-106338","document":"tm2625057-4_4seq1.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/2027157/000110465926106338/tm2625057-4_4seq1.xml","form_type":"4"}},{"id":4613344,"issuer":{"id":9597,"kind":"organization","name":"Barinthus Biotherapeutics plc.","symbol":"BRNS"},"owners":[{"id":83565,"kind":"person","name":"Hooftman Leon","position":1,"cik":"0002027157","reported_name":"Hooftman Leon","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Medical Officer"}}],"security":"Ordinary Shares","published_at":"2026-09-09T20:19:07.000Z","date":"2026-09-09","kind":"grant","planned":false,"acquired":true,"shares":361530,"ownership":{"direct":true},"footnotes":[{"field":"security","element":"securityTitle","label":"F1","text":"The Ordinary Shares may be represented by American Depositary Shares (\"ADSs\" and together with the Ordinary Shares, the \"Shares\"), each of which currently represents one Ordinary Share."},{"field":"kind","element":"transactionCoding","label":"F2","text":"This Form 4 reports securities transacted in connection with the Agreement and Plan of Merger, dated September 29, 2025, as amended (the \"Merger Agreement\") by and among the Issuer, Beacon Topco, Inc. (\"Topco\"), a Delaware corporation and a direct wholly owned subsidiary of the Issuer, Cdog Merger Sub, Inc., a Delaware corporation and a direct wholly owned subsidiary of Topco, and Clywedog Therapeutics, Inc., a Delaware corporation. On September 9, 2026 (the \"Effective Time\"), in connection with the effectiveness of the scheme of arrangement under Part 26 of the United Kingdom Companies Act 2006 (the \"Scheme\") contemplated by the Merger Agreement, Topco acquired the entire issued share capital of the Issuer, resulting in the Issuer becoming a direct wholly owned subsidiary of Topco."},{"field":"shares","element":"transactionShares","label":"F3","text":"Represents restricted share units (\"RSUs\") previously granted to the Reporting Person, vesting of which was subject to completion of the transactions contemplated by the Merger Agreement. Each RSU represented the contingent right to receive one Share of the Issuer. At the Effective time, each RSU, whether or not then vested, was automatically released in consideration of the assumption of such RSU by Topco and converted into an RSU relating to the common stock, $0.0001 par value per share, of Topco (the \"Topco Common Stock\")."},{"field":"price","element":"transactionPricePerShare","label":"F3","text":"Represents restricted share units (\"RSUs\") previously granted to the Reporting Person, vesting of which was subject to completion of the transactions contemplated by the Merger Agreement. Each RSU represented the contingent right to receive one Share of the Issuer. At the Effective time, each RSU, whether or not then vested, was automatically released in consideration of the assumption of such RSU by Topco and converted into an RSU relating to the common stock, $0.0001 par value per share, of Topco (the \"Topco Common Stock\")."}],"balance_after":361530,"source":{"system":"sec-edgar","filing":"0001104659-26-106338","document":"tm2625057-4_4seq1.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/2027157/000110465926106338/tm2625057-4_4seq1.xml","form_type":"4"}},{"id":4613343,"issuer":{"id":9597,"kind":"organization","name":"Barinthus Biotherapeutics plc.","symbol":"BRNS"},"owners":[{"id":78629,"kind":"person","name":"Hammacher Alex","position":1,"cik":"0001851633","reported_name":"Hammacher Alex","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Share Option (Right to Buy)","published_at":"2026-09-09T20:18:35.000Z","date":"2026-09-09","kind":"disposition_to_issuer","planned":false,"acquired":false,"shares":20174,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F2","text":"This Form 4 reports securities transacted in connection with the Agreement and Plan of Merger, dated September 29, 2025, as amended (the \"Merger Agreement\") by and among the Issuer, Beacon Topco, Inc. (\"Topco\"), a Delaware corporation and a direct wholly owned subsidiary of the Issuer, Cdog Merger Sub, Inc., a Delaware corporation and a direct wholly owned subsidiary of Topco, and Clywedog Therapeutics, Inc., a Delaware corporation. On September 9, 2026 (the \"Effective Time\"), in connection with the effectiveness of the scheme of arrangement under Part 26 of the United Kingdom Companies Act 2006 (the \"Scheme\") contemplated by the Merger Agreement, Topco acquired the entire issued share capital of the Issuer, resulting in the Issuer becoming a direct wholly owned subsidiary of Topco."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F4","text":"Pursuant to the Merger Agreement, at the Effective Time, each option to acquire Shares under the Issuer's equity plans that was outstanding as of immediately prior to the Effective Time ceased to represent a right to acquire Shares of the Issuer, and was converted into an option to acquire shares of Topco Common Stock and assumed by Topco on the same terms and conditions (including applicable vesting and exercisability conditions) as were applicable to such option immediately prior to the Effective Time."},{"field":"derivative.underlying","element":"underlyingSecurityTitle","label":"F1","text":"The Ordinary Shares may be represented by American Depositary Shares (\"ADSs\" and together with the Ordinary Shares, the \"Shares\"), each of which currently represents one Ordinary Share."}],"balance_after":0,"derivative":{"exercise_price":1,"expiration_date":"2035-06-10","underlying":"Ordinary Shares","underlying_shares":20174},"source":{"system":"sec-edgar","filing":"0001104659-26-106337","document":"tm2625057-3_4seq1.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":6,"url":"https://www.sec.gov/Archives/edgar/data/1851633/000110465926106337/tm2625057-3_4seq1.xml","form_type":"4"}},{"id":4613342,"issuer":{"id":9597,"kind":"organization","name":"Barinthus Biotherapeutics plc.","symbol":"BRNS"},"owners":[{"id":78629,"kind":"person","name":"Hammacher Alex","position":1,"cik":"0001851633","reported_name":"Hammacher Alex","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Share Option (Right to Buy)","published_at":"2026-09-09T20:18:35.000Z","date":"2026-09-09","kind":"disposition_to_issuer","planned":false,"acquired":false,"shares":19516,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F2","text":"This Form 4 reports securities transacted in connection with the Agreement and Plan of Merger, dated September 29, 2025, as amended (the \"Merger Agreement\") by and among the Issuer, Beacon Topco, Inc. (\"Topco\"), a Delaware corporation and a direct wholly owned subsidiary of the Issuer, Cdog Merger Sub, Inc., a Delaware corporation and a direct wholly owned subsidiary of Topco, and Clywedog Therapeutics, Inc., a Delaware corporation. On September 9, 2026 (the \"Effective Time\"), in connection with the effectiveness of the scheme of arrangement under Part 26 of the United Kingdom Companies Act 2006 (the \"Scheme\") contemplated by the Merger Agreement, Topco acquired the entire issued share capital of the Issuer, resulting in the Issuer becoming a direct wholly owned subsidiary of Topco."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F4","text":"Pursuant to the Merger Agreement, at the Effective Time, each option to acquire Shares under the Issuer's equity plans that was outstanding as of immediately prior to the Effective Time ceased to represent a right to acquire Shares of the Issuer, and was converted into an option to acquire shares of Topco Common Stock and assumed by Topco on the same terms and conditions (including applicable vesting and exercisability conditions) as were applicable to such option immediately prior to the Effective Time."},{"field":"derivative.underlying","element":"underlyingSecurityTitle","label":"F1","text":"The Ordinary Shares may be represented by American Depositary Shares (\"ADSs\" and together with the Ordinary Shares, the \"Shares\"), each of which currently represents one Ordinary Share."}],"balance_after":0,"derivative":{"exercise_price":2.34,"expiration_date":"2034-05-10","underlying":"Ordinary Shares","underlying_shares":19516},"source":{"system":"sec-edgar","filing":"0001104659-26-106337","document":"tm2625057-3_4seq1.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":5,"url":"https://www.sec.gov/Archives/edgar/data/1851633/000110465926106337/tm2625057-3_4seq1.xml","form_type":"4"}},{"id":4613341,"issuer":{"id":9597,"kind":"organization","name":"Barinthus Biotherapeutics plc.","symbol":"BRNS"},"owners":[{"id":78629,"kind":"person","name":"Hammacher Alex","position":1,"cik":"0001851633","reported_name":"Hammacher Alex","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Share Option (Right to Buy)","published_at":"2026-09-09T20:18:35.000Z","date":"2026-09-09","kind":"disposition_to_issuer","planned":false,"acquired":false,"shares":19197,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F2","text":"This Form 4 reports securities transacted in connection with the Agreement and Plan of Merger, dated September 29, 2025, as amended (the \"Merger Agreement\") by and among the Issuer, Beacon Topco, Inc. (\"Topco\"), a Delaware corporation and a direct wholly owned subsidiary of the Issuer, Cdog Merger Sub, Inc., a Delaware corporation and a direct wholly owned subsidiary of Topco, and Clywedog Therapeutics, Inc., a Delaware corporation. On September 9, 2026 (the \"Effective Time\"), in connection with the effectiveness of the scheme of arrangement under Part 26 of the United Kingdom Companies Act 2006 (the \"Scheme\") contemplated by the Merger Agreement, Topco acquired the entire issued share capital of the Issuer, resulting in the Issuer becoming a direct wholly owned subsidiary of Topco."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F4","text":"Pursuant to the Merger Agreement, at the Effective Time, each option to acquire Shares under the Issuer's equity plans that was outstanding as of immediately prior to the Effective Time ceased to represent a right to acquire Shares of the Issuer, and was converted into an option to acquire shares of Topco Common Stock and assumed by Topco on the same terms and conditions (including applicable vesting and exercisability conditions) as were applicable to such option immediately prior to the Effective Time."},{"field":"derivative.underlying","element":"underlyingSecurityTitle","label":"F1","text":"The Ordinary Shares may be represented by American Depositary Shares (\"ADSs\" and together with the Ordinary Shares, the \"Shares\"), each of which currently represents one Ordinary Share."}],"balance_after":0,"derivative":{"exercise_price":2.27,"expiration_date":"2033-05-11","underlying":"Ordinary Shares","underlying_shares":19197},"source":{"system":"sec-edgar","filing":"0001104659-26-106337","document":"tm2625057-3_4seq1.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":4,"url":"https://www.sec.gov/Archives/edgar/data/1851633/000110465926106337/tm2625057-3_4seq1.xml","form_type":"4"}},{"id":4613340,"issuer":{"id":9597,"kind":"organization","name":"Barinthus Biotherapeutics plc.","symbol":"BRNS"},"owners":[{"id":78629,"kind":"person","name":"Hammacher Alex","position":1,"cik":"0001851633","reported_name":"Hammacher Alex","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Share Option (Right to Buy)","published_at":"2026-09-09T20:18:35.000Z","date":"2026-09-09","kind":"disposition_to_issuer","planned":false,"acquired":false,"shares":18604,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F2","text":"This Form 4 reports securities transacted in connection with the Agreement and Plan of Merger, dated September 29, 2025, as amended (the \"Merger Agreement\") by and among the Issuer, Beacon Topco, Inc. (\"Topco\"), a Delaware corporation and a direct wholly owned subsidiary of the Issuer, Cdog Merger Sub, Inc., a Delaware corporation and a direct wholly owned subsidiary of Topco, and Clywedog Therapeutics, Inc., a Delaware corporation. On September 9, 2026 (the \"Effective Time\"), in connection with the effectiveness of the scheme of arrangement under Part 26 of the United Kingdom Companies Act 2006 (the \"Scheme\") contemplated by the Merger Agreement, Topco acquired the entire issued share capital of the Issuer, resulting in the Issuer becoming a direct wholly owned subsidiary of Topco."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F4","text":"Pursuant to the Merger Agreement, at the Effective Time, each option to acquire Shares under the Issuer's equity plans that was outstanding as of immediately prior to the Effective Time ceased to represent a right to acquire Shares of the Issuer, and was converted into an option to acquire shares of Topco Common Stock and assumed by Topco on the same terms and conditions (including applicable vesting and exercisability conditions) as were applicable to such option immediately prior to the Effective Time."},{"field":"derivative.underlying","element":"underlyingSecurityTitle","label":"F1","text":"The Ordinary Shares may be represented by American Depositary Shares (\"ADSs\" and together with the Ordinary Shares, the \"Shares\"), each of which currently represents one Ordinary Share."}],"balance_after":0,"derivative":{"exercise_price":4.27,"expiration_date":"2032-06-15","underlying":"Ordinary Shares","underlying_shares":18604},"source":{"system":"sec-edgar","filing":"0001104659-26-106337","document":"tm2625057-3_4seq1.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":3,"url":"https://www.sec.gov/Archives/edgar/data/1851633/000110465926106337/tm2625057-3_4seq1.xml","form_type":"4"}},{"id":4613339,"issuer":{"id":9597,"kind":"organization","name":"Barinthus Biotherapeutics plc.","symbol":"BRNS"},"owners":[{"id":78629,"kind":"person","name":"Hammacher Alex","position":1,"cik":"0001851633","reported_name":"Hammacher Alex","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Share Option (Right to Buy)","published_at":"2026-09-09T20:18:35.000Z","date":"2026-09-09","kind":"disposition_to_issuer","planned":false,"acquired":false,"shares":34328,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F2","text":"This Form 4 reports securities transacted in connection with the Agreement and Plan of Merger, dated September 29, 2025, as amended (the \"Merger Agreement\") by and among the Issuer, Beacon Topco, Inc. (\"Topco\"), a Delaware corporation and a direct wholly owned subsidiary of the Issuer, Cdog Merger Sub, Inc., a Delaware corporation and a direct wholly owned subsidiary of Topco, and Clywedog Therapeutics, Inc., a Delaware corporation. On September 9, 2026 (the \"Effective Time\"), in connection with the effectiveness of the scheme of arrangement under Part 26 of the United Kingdom Companies Act 2006 (the \"Scheme\") contemplated by the Merger Agreement, Topco acquired the entire issued share capital of the Issuer, resulting in the Issuer becoming a direct wholly owned subsidiary of Topco."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F4","text":"Pursuant to the Merger Agreement, at the Effective Time, each option to acquire Shares under the Issuer's equity plans that was outstanding as of immediately prior to the Effective Time ceased to represent a right to acquire Shares of the Issuer, and was converted into an option to acquire shares of Topco Common Stock and assumed by Topco on the same terms and conditions (including applicable vesting and exercisability conditions) as were applicable to such option immediately prior to the Effective Time."},{"field":"derivative.underlying","element":"underlyingSecurityTitle","label":"F1","text":"The Ordinary Shares may be represented by American Depositary Shares (\"ADSs\" and together with the Ordinary Shares, the \"Shares\"), each of which currently represents one Ordinary Share."}],"balance_after":0,"derivative":{"exercise_price":17,"expiration_date":"2031-05-01","underlying":"Ordinary Shares","underlying_shares":34328},"source":{"system":"sec-edgar","filing":"0001104659-26-106337","document":"tm2625057-3_4seq1.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1851633/000110465926106337/tm2625057-3_4seq1.xml","form_type":"4"}},{"id":4613338,"issuer":{"id":9597,"kind":"organization","name":"Barinthus Biotherapeutics plc.","symbol":"BRNS"},"owners":[{"id":78629,"kind":"person","name":"Hammacher Alex","position":1,"cik":"0001851633","reported_name":"Hammacher Alex","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Ordinary Shares","published_at":"2026-09-09T20:18:35.000Z","date":"2026-09-09","kind":"disposition_to_issuer","planned":false,"acquired":false,"shares":3000,"ownership":{"direct":true},"footnotes":[{"field":"security","element":"securityTitle","label":"F1","text":"The Ordinary Shares may be represented by American Depositary Shares (\"ADSs\" and together with the Ordinary Shares, the \"Shares\"), each of which currently represents one Ordinary Share."},{"field":"kind","element":"transactionCoding","label":"F2","text":"This Form 4 reports securities transacted in connection with the Agreement and Plan of Merger, dated September 29, 2025, as amended (the \"Merger Agreement\") by and among the Issuer, Beacon Topco, Inc. (\"Topco\"), a Delaware corporation and a direct wholly owned subsidiary of the Issuer, Cdog Merger Sub, Inc., a Delaware corporation and a direct wholly owned subsidiary of Topco, and Clywedog Therapeutics, Inc., a Delaware corporation. On September 9, 2026 (the \"Effective Time\"), in connection with the effectiveness of the scheme of arrangement under Part 26 of the United Kingdom Companies Act 2006 (the \"Scheme\") contemplated by the Merger Agreement, Topco acquired the entire issued share capital of the Issuer, resulting in the Issuer becoming a direct wholly owned subsidiary of Topco."},{"field":"shares","element":"transactionShares","label":"F3","text":"Pursuant to the Merger Agreement and in connection with the effectiveness of the Scheme, at the Effective Time, each Share of the Issuer was converted into the right to receive 0.111 shares of common stock, $0.0001 par value per share, of Topco (the \"Topco Common Stock\")."},{"field":"price","element":"transactionPricePerShare","label":"F3","text":"Pursuant to the Merger Agreement and in connection with the effectiveness of the Scheme, at the Effective Time, each Share of the Issuer was converted into the right to receive 0.111 shares of common stock, $0.0001 par value per share, of Topco (the \"Topco Common Stock\")."}],"balance_after":0,"source":{"system":"sec-edgar","filing":"0001104659-26-106337","document":"tm2625057-3_4seq1.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1851633/000110465926106337/tm2625057-3_4seq1.xml","form_type":"4"}},{"id":4613337,"issuer":{"id":9597,"kind":"organization","name":"Barinthus Biotherapeutics plc.","symbol":"BRNS"},"owners":[{"id":38019,"kind":"person","name":"Enright William","position":1,"cik":"0001705564","reported_name":"Enright William","relationship":{"director":true,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Executive Officer"}}],"security":"Share Option (Right to Buy)","published_at":"2026-09-09T20:18:00.000Z","date":"2026-09-09","kind":"disposition_to_issuer","planned":false,"acquired":false,"shares":600000,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F2","text":"This Form 4 reports securities transacted in connection with the Agreement and Plan of Merger, dated September 29, 2025, as amended (the \"Merger Agreement\") by and among the Issuer, Beacon Topco, Inc. (\"Topco\"), a Delaware corporation and a direct wholly owned subsidiary of the Issuer, Cdog Merger Sub, Inc., a Delaware corporation and a direct wholly owned subsidiary of Topco, and Clywedog Therapeutics, Inc., a Delaware corporation. On September 9, 2026 (the \"Effective Time\"), in connection with the effectiveness of the scheme of arrangement under Part 26 of the United Kingdom Companies Act 2006 (the \"Scheme\") contemplated by the Merger Agreement, Topco acquired the entire issued share capital of the Issuer, resulting in the Issuer becoming a direct wholly owned subsidiary of Topco."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F6","text":"Pursuant to the Merger Agreement, at the Effective Time, each option to acquire Shares under the Issuer's equity plans that was outstanding as of immediately prior to the Effective Time ceased to represent a right to acquire Shares of the Issuer, and was converted into an option to acquire shares of Topco Common Stock and assumed by Topco on the same terms and conditions (including applicable vesting and exercisability conditions) as were applicable to such option immediately prior to the Effective Time."},{"field":"derivative.underlying","element":"underlyingSecurityTitle","label":"F1","text":"The Ordinary Shares may be represented by American Depositary Shares (\"ADSs\" and together with the Ordinary Shares, the \"Shares\"), each of which currently represents one Ordinary Share."}],"balance_after":0,"derivative":{"exercise_price":1,"expiration_date":"2035-02-03","underlying":"Ordinary Shares","underlying_shares":600000},"source":{"system":"sec-edgar","filing":"0001104659-26-106336","document":"tm2625057-2_4seq1.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":7,"url":"https://www.sec.gov/Archives/edgar/data/1828185/000110465926106336/tm2625057-2_4seq1.xml","form_type":"4"}},{"id":4613336,"issuer":{"id":9597,"kind":"organization","name":"Barinthus Biotherapeutics plc.","symbol":"BRNS"},"owners":[{"id":38019,"kind":"person","name":"Enright William","position":1,"cik":"0001705564","reported_name":"Enright William","relationship":{"director":true,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Executive Officer"}}],"security":"Share Option (Right to Buy)","published_at":"2026-09-09T20:18:00.000Z","date":"2026-09-09","kind":"disposition_to_issuer","planned":false,"acquired":false,"shares":443981,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F2","text":"This Form 4 reports securities transacted in connection with the Agreement and Plan of Merger, dated September 29, 2025, as amended (the \"Merger Agreement\") by and among the Issuer, Beacon Topco, Inc. (\"Topco\"), a Delaware corporation and a direct wholly owned subsidiary of the Issuer, Cdog Merger Sub, Inc., a Delaware corporation and a direct wholly owned subsidiary of Topco, and Clywedog Therapeutics, Inc., a Delaware corporation. On September 9, 2026 (the \"Effective Time\"), in connection with the effectiveness of the scheme of arrangement under Part 26 of the United Kingdom Companies Act 2006 (the \"Scheme\") contemplated by the Merger Agreement, Topco acquired the entire issued share capital of the Issuer, resulting in the Issuer becoming a direct wholly owned subsidiary of Topco."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F6","text":"Pursuant to the Merger Agreement, at the Effective Time, each option to acquire Shares under the Issuer's equity plans that was outstanding as of immediately prior to the Effective Time ceased to represent a right to acquire Shares of the Issuer, and was converted into an option to acquire shares of Topco Common Stock and assumed by Topco on the same terms and conditions (including applicable vesting and exercisability conditions) as were applicable to such option immediately prior to the Effective Time."},{"field":"derivative.underlying","element":"underlyingSecurityTitle","label":"F1","text":"The Ordinary Shares may be represented by American Depositary Shares (\"ADSs\" and together with the Ordinary Shares, the \"Shares\"), each of which currently represents one Ordinary Share."}],"balance_after":0,"derivative":{"exercise_price":3.7,"expiration_date":"2034-01-02","underlying":"Ordinary Shares","underlying_shares":443981},"source":{"system":"sec-edgar","filing":"0001104659-26-106336","document":"tm2625057-2_4seq1.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":6,"url":"https://www.sec.gov/Archives/edgar/data/1828185/000110465926106336/tm2625057-2_4seq1.xml","form_type":"4"}},{"id":4613335,"issuer":{"id":9597,"kind":"organization","name":"Barinthus Biotherapeutics plc.","symbol":"BRNS"},"owners":[{"id":38019,"kind":"person","name":"Enright William","position":1,"cik":"0001705564","reported_name":"Enright William","relationship":{"director":true,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Executive Officer"}}],"security":"Share Option (Right to Buy)","published_at":"2026-09-09T20:18:00.000Z","date":"2026-09-09","kind":"disposition_to_issuer","planned":false,"acquired":false,"shares":440000,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F2","text":"This Form 4 reports securities transacted in connection with the Agreement and Plan of Merger, dated September 29, 2025, as amended (the \"Merger Agreement\") by and among the Issuer, Beacon Topco, Inc. (\"Topco\"), a Delaware corporation and a direct wholly owned subsidiary of the Issuer, Cdog Merger Sub, Inc., a Delaware corporation and a direct wholly owned subsidiary of Topco, and Clywedog Therapeutics, Inc., a Delaware corporation. On September 9, 2026 (the \"Effective Time\"), in connection with the effectiveness of the scheme of arrangement under Part 26 of the United Kingdom Companies Act 2006 (the \"Scheme\") contemplated by the Merger Agreement, Topco acquired the entire issued share capital of the Issuer, resulting in the Issuer becoming a direct wholly owned subsidiary of Topco."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F6","text":"Pursuant to the Merger Agreement, at the Effective Time, each option to acquire Shares under the Issuer's equity plans that was outstanding as of immediately prior to the Effective Time ceased to represent a right to acquire Shares of the Issuer, and was converted into an option to acquire shares of Topco Common Stock and assumed by Topco on the same terms and conditions (including applicable vesting and exercisability conditions) as were applicable to such option immediately prior to the Effective Time."},{"field":"derivative.underlying","element":"underlyingSecurityTitle","label":"F1","text":"The Ordinary Shares may be represented by American Depositary Shares (\"ADSs\" and together with the Ordinary Shares, the \"Shares\"), each of which currently represents one Ordinary Share."}],"balance_after":0,"derivative":{"exercise_price":2.4,"expiration_date":"2033-01-03","underlying":"Ordinary Shares","underlying_shares":440000},"source":{"system":"sec-edgar","filing":"0001104659-26-106336","document":"tm2625057-2_4seq1.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":5,"url":"https://www.sec.gov/Archives/edgar/data/1828185/000110465926106336/tm2625057-2_4seq1.xml","form_type":"4"}},{"id":4613334,"issuer":{"id":9597,"kind":"organization","name":"Barinthus Biotherapeutics plc.","symbol":"BRNS"},"owners":[{"id":38019,"kind":"person","name":"Enright William","position":1,"cik":"0001705564","reported_name":"Enright William","relationship":{"director":true,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Executive Officer"}}],"security":"Share Option (Right to Buy)","published_at":"2026-09-09T20:18:00.000Z","date":"2026-09-09","kind":"disposition_to_issuer","planned":false,"acquired":false,"shares":359605,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F2","text":"This Form 4 reports securities transacted in connection with the Agreement and Plan of Merger, dated September 29, 2025, as amended (the \"Merger Agreement\") by and among the Issuer, Beacon Topco, Inc. (\"Topco\"), a Delaware corporation and a direct wholly owned subsidiary of the Issuer, Cdog Merger Sub, Inc., a Delaware corporation and a direct wholly owned subsidiary of Topco, and Clywedog Therapeutics, Inc., a Delaware corporation. On September 9, 2026 (the \"Effective Time\"), in connection with the effectiveness of the scheme of arrangement under Part 26 of the United Kingdom Companies Act 2006 (the \"Scheme\") contemplated by the Merger Agreement, Topco acquired the entire issued share capital of the Issuer, resulting in the Issuer becoming a direct wholly owned subsidiary of Topco."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F6","text":"Pursuant to the Merger Agreement, at the Effective Time, each option to acquire Shares under the Issuer's equity plans that was outstanding as of immediately prior to the Effective Time ceased to represent a right to acquire Shares of the Issuer, and was converted into an option to acquire shares of Topco Common Stock and assumed by Topco on the same terms and conditions (including applicable vesting and exercisability conditions) as were applicable to such option immediately prior to the Effective Time."},{"field":"derivative.underlying","element":"underlyingSecurityTitle","label":"F1","text":"The Ordinary Shares may be represented by American Depositary Shares (\"ADSs\" and together with the Ordinary Shares, the \"Shares\"), each of which currently represents one Ordinary Share."}],"balance_after":0,"derivative":{"exercise_price":11.12,"expiration_date":"2032-03-14","underlying":"Ordinary Shares","underlying_shares":359605},"source":{"system":"sec-edgar","filing":"0001104659-26-106336","document":"tm2625057-2_4seq1.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":4,"url":"https://www.sec.gov/Archives/edgar/data/1828185/000110465926106336/tm2625057-2_4seq1.xml","form_type":"4"}},{"id":4613333,"issuer":{"id":9597,"kind":"organization","name":"Barinthus Biotherapeutics plc.","symbol":"BRNS"},"owners":[{"id":38019,"kind":"person","name":"Enright William","position":1,"cik":"0001705564","reported_name":"Enright William","relationship":{"director":true,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Executive Officer"}}],"security":"Share Option (Right to Buy)","published_at":"2026-09-09T20:18:00.000Z","date":"2026-09-09","kind":"disposition_to_issuer","planned":false,"acquired":false,"shares":176130,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F2","text":"This Form 4 reports securities transacted in connection with the Agreement and Plan of Merger, dated September 29, 2025, as amended (the \"Merger Agreement\") by and among the Issuer, Beacon Topco, Inc. (\"Topco\"), a Delaware corporation and a direct wholly owned subsidiary of the Issuer, Cdog Merger Sub, Inc., a Delaware corporation and a direct wholly owned subsidiary of Topco, and Clywedog Therapeutics, Inc., a Delaware corporation. On September 9, 2026 (the \"Effective Time\"), in connection with the effectiveness of the scheme of arrangement under Part 26 of the United Kingdom Companies Act 2006 (the \"Scheme\") contemplated by the Merger Agreement, Topco acquired the entire issued share capital of the Issuer, resulting in the Issuer becoming a direct wholly owned subsidiary of Topco."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F6","text":"Pursuant to the Merger Agreement, at the Effective Time, each option to acquire Shares under the Issuer's equity plans that was outstanding as of immediately prior to the Effective Time ceased to represent a right to acquire Shares of the Issuer, and was converted into an option to acquire shares of Topco Common Stock and assumed by Topco on the same terms and conditions (including applicable vesting and exercisability conditions) as were applicable to such option immediately prior to the Effective Time."},{"field":"derivative.underlying","element":"underlyingSecurityTitle","label":"F1","text":"The Ordinary Shares may be represented by American Depositary Shares (\"ADSs\" and together with the Ordinary Shares, the \"Shares\"), each of which currently represents one Ordinary Share."}],"balance_after":0,"derivative":{"exercise_price":17,"expiration_date":"2031-05-01","underlying":"Ordinary Shares","underlying_shares":176130},"source":{"system":"sec-edgar","filing":"0001104659-26-106336","document":"tm2625057-2_4seq1.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":3,"url":"https://www.sec.gov/Archives/edgar/data/1828185/000110465926106336/tm2625057-2_4seq1.xml","form_type":"4"}},{"id":4613332,"issuer":{"id":9597,"kind":"organization","name":"Barinthus Biotherapeutics plc.","symbol":"BRNS"},"owners":[{"id":38019,"kind":"person","name":"Enright William","position":1,"cik":"0001705564","reported_name":"Enright William","relationship":{"director":true,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Executive Officer"}}],"security":"Ordinary Shares","published_at":"2026-09-09T20:18:00.000Z","date":"2026-09-09","kind":"disposition_to_issuer","planned":false,"acquired":false,"shares":514923,"ownership":{"direct":false,"nature":"By Trust"},"footnotes":[{"field":"security","element":"securityTitle","label":"F1","text":"The Ordinary Shares may be represented by American Depositary Shares (\"ADSs\" and together with the Ordinary Shares, the \"Shares\"), each of which currently represents one Ordinary Share."},{"field":"kind","element":"transactionCoding","label":"F2","text":"This Form 4 reports securities transacted in connection with the Agreement and Plan of Merger, dated September 29, 2025, as amended (the \"Merger Agreement\") by and among the Issuer, Beacon Topco, Inc. (\"Topco\"), a Delaware corporation and a direct wholly owned subsidiary of the Issuer, Cdog Merger Sub, Inc., a Delaware corporation and a direct wholly owned subsidiary of Topco, and Clywedog Therapeutics, Inc., a Delaware corporation. On September 9, 2026 (the \"Effective Time\"), in connection with the effectiveness of the scheme of arrangement under Part 26 of the United Kingdom Companies Act 2006 (the \"Scheme\") contemplated by the Merger Agreement, Topco acquired the entire issued share capital of the Issuer, resulting in the Issuer becoming a direct wholly owned subsidiary of Topco."},{"field":"shares","element":"transactionShares","label":"F3","text":"Pursuant to the Merger Agreement and in connection with the effectiveness of the Scheme, at the Effective Time, each Share of the Issuer was converted into the right to receive 0.111 shares of common stock, $0.0001 par value per share, of Topco (the \"Topco Common Stock\")."},{"field":"price","element":"transactionPricePerShare","label":"F3","text":"Pursuant to the Merger Agreement and in connection with the effectiveness of the Scheme, at the Effective Time, each Share of the Issuer was converted into the right to receive 0.111 shares of common stock, $0.0001 par value per share, of Topco (the \"Topco Common Stock\")."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F5","text":"Shares held by William Enright Revocable Trust, of which the Reporting Person serves as trustee. The Reporting Person disclaims beneficial ownership of the shares held by such trust for purposes of Section 16 of the Exchange Act, except to the extent of his pecuniary interest therein, if any."}],"balance_after":0,"source":{"system":"sec-edgar","filing":"0001104659-26-106336","document":"tm2625057-2_4seq1.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1828185/000110465926106336/tm2625057-2_4seq1.xml","form_type":"4"}},{"id":4613331,"issuer":{"id":9597,"kind":"organization","name":"Barinthus Biotherapeutics plc.","symbol":"BRNS"},"owners":[{"id":38019,"kind":"person","name":"Enright William","position":1,"cik":"0001705564","reported_name":"Enright William","relationship":{"director":true,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Executive Officer"}}],"security":"Ordinary Shares","published_at":"2026-09-09T20:18:00.000Z","date":"2026-09-09","kind":"disposition_to_issuer","planned":false,"acquired":false,"shares":728454,"ownership":{"direct":false,"nature":"By Trust"},"footnotes":[{"field":"security","element":"securityTitle","label":"F1","text":"The Ordinary Shares may be represented by American Depositary Shares (\"ADSs\" and together with the Ordinary Shares, the \"Shares\"), each of which currently represents one Ordinary Share."},{"field":"kind","element":"transactionCoding","label":"F2","text":"This Form 4 reports securities transacted in connection with the Agreement and Plan of Merger, dated September 29, 2025, as amended (the \"Merger Agreement\") by and among the Issuer, Beacon Topco, Inc. (\"Topco\"), a Delaware corporation and a direct wholly owned subsidiary of the Issuer, Cdog Merger Sub, Inc., a Delaware corporation and a direct wholly owned subsidiary of Topco, and Clywedog Therapeutics, Inc., a Delaware corporation. On September 9, 2026 (the \"Effective Time\"), in connection with the effectiveness of the scheme of arrangement under Part 26 of the United Kingdom Companies Act 2006 (the \"Scheme\") contemplated by the Merger Agreement, Topco acquired the entire issued share capital of the Issuer, resulting in the Issuer becoming a direct wholly owned subsidiary of Topco."},{"field":"shares","element":"transactionShares","label":"F3","text":"Pursuant to the Merger Agreement and in connection with the effectiveness of the Scheme, at the Effective Time, each Share of the Issuer was converted into the right to receive 0.111 shares of common stock, $0.0001 par value per share, of Topco (the \"Topco Common Stock\")."},{"field":"price","element":"transactionPricePerShare","label":"F3","text":"Pursuant to the Merger Agreement and in connection with the effectiveness of the Scheme, at the Effective Time, each Share of the Issuer was converted into the right to receive 0.111 shares of common stock, $0.0001 par value per share, of Topco (the \"Topco Common Stock\")."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F4","text":"Shares held by William J Enright TR UA Dated 03/04/2021 Enright Family 2021 Irrevocable Trust, of which the Reporting Person serves as trustee. The Reporting Person disclaims beneficial ownership of the shares held by such trust for purposes of Section 16 of the Exchange Act, except to the extent of his pecuniary interest therein, if any."}],"balance_after":0,"source":{"system":"sec-edgar","filing":"0001104659-26-106336","document":"tm2625057-2_4seq1.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1828185/000110465926106336/tm2625057-2_4seq1.xml","form_type":"4"}},{"id":4613296,"issuer":{"id":9597,"kind":"organization","name":"Barinthus Biotherapeutics plc.","symbol":"BRNS"},"owners":[{"id":46694,"kind":"person","name":"DAWES KAREN A","position":1,"cik":"0001261506","reported_name":"DAWES KAREN A","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Share Option (Right to Buy)","published_at":"2026-09-09T20:15:12.000Z","date":"2026-09-09","kind":"disposition_to_issuer","planned":false,"acquired":false,"shares":20174,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F2","text":"This Form 4 reports securities transacted in connection with the Agreement and Plan of Merger, dated September 29, 2025, as amended (the \"Merger Agreement\") by and among the Issuer, Beacon Topco, Inc. (\"Topco\"), a Delaware corporation and a direct wholly owned subsidiary of the Issuer, Cdog Merger Sub, Inc., a Delaware corporation and a direct wholly owned subsidiary of Topco, and Clywedog Therapeutics, Inc., a Delaware corporation. On September 9, 2026 (the \"Effective Time\"), in connection with the effectiveness of the scheme of arrangement under Part 26 of the United Kingdom Companies Act 2006 (the \"Scheme\") contemplated by the Merger Agreement, Topco acquired the entire issued share capital of the Issuer, resulting in the Issuer becoming a direct wholly owned subsidiary of Topco."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F4","text":"Pursuant to the Merger Agreement, at the Effective Time, each option to acquire Shares under the Issuer's equity plans that was outstanding as of immediately prior to the Effective Time ceased to represent a right to acquire Shares of the Issuer, and was converted into an option to acquire shares of Topco Common Stock and assumed by Topco on the same terms and conditions (including applicable vesting and exercisability conditions) as were applicable to such option immediately prior to the Effective Time."},{"field":"derivative.underlying","element":"underlyingSecurityTitle","label":"F1","text":"The Ordinary Shares may be represented by American Depositary Shares (\"ADSs\" and together with the Ordinary Shares, the \"Shares\"), each of which currently represents one Ordinary Share."}],"balance_after":0,"derivative":{"exercise_price":1,"expiration_date":"2035-06-10","underlying":"Ordinary Shares","underlying_shares":20174},"source":{"system":"sec-edgar","filing":"0001104659-26-106323","document":"tm2625057-1_4seq1.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":6,"url":"https://www.sec.gov/Archives/edgar/data/1828185/000110465926106323/tm2625057-1_4seq1.xml","form_type":"4"}},{"id":4613295,"issuer":{"id":9597,"kind":"organization","name":"Barinthus Biotherapeutics plc.","symbol":"BRNS"},"owners":[{"id":46694,"kind":"person","name":"DAWES KAREN A","position":1,"cik":"0001261506","reported_name":"DAWES KAREN A","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Share Option (Right to Buy)","published_at":"2026-09-09T20:15:12.000Z","date":"2026-09-09","kind":"disposition_to_issuer","planned":false,"acquired":false,"shares":19516,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F2","text":"This Form 4 reports securities transacted in connection with the Agreement and Plan of Merger, dated September 29, 2025, as amended (the \"Merger Agreement\") by and among the Issuer, Beacon Topco, Inc. (\"Topco\"), a Delaware corporation and a direct wholly owned subsidiary of the Issuer, Cdog Merger Sub, Inc., a Delaware corporation and a direct wholly owned subsidiary of Topco, and Clywedog Therapeutics, Inc., a Delaware corporation. On September 9, 2026 (the \"Effective Time\"), in connection with the effectiveness of the scheme of arrangement under Part 26 of the United Kingdom Companies Act 2006 (the \"Scheme\") contemplated by the Merger Agreement, Topco acquired the entire issued share capital of the Issuer, resulting in the Issuer becoming a direct wholly owned subsidiary of Topco."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F4","text":"Pursuant to the Merger Agreement, at the Effective Time, each option to acquire Shares under the Issuer's equity plans that was outstanding as of immediately prior to the Effective Time ceased to represent a right to acquire Shares of the Issuer, and was converted into an option to acquire shares of Topco Common Stock and assumed by Topco on the same terms and conditions (including applicable vesting and exercisability conditions) as were applicable to such option immediately prior to the Effective Time."},{"field":"derivative.underlying","element":"underlyingSecurityTitle","label":"F1","text":"The Ordinary Shares may be represented by American Depositary Shares (\"ADSs\" and together with the Ordinary Shares, the \"Shares\"), each of which currently represents one Ordinary Share."}],"balance_after":0,"derivative":{"exercise_price":2.34,"expiration_date":"2034-05-10","underlying":"Ordinary Shares","underlying_shares":19516},"source":{"system":"sec-edgar","filing":"0001104659-26-106323","document":"tm2625057-1_4seq1.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":5,"url":"https://www.sec.gov/Archives/edgar/data/1828185/000110465926106323/tm2625057-1_4seq1.xml","form_type":"4"}},{"id":4613294,"issuer":{"id":9597,"kind":"organization","name":"Barinthus Biotherapeutics plc.","symbol":"BRNS"},"owners":[{"id":46694,"kind":"person","name":"DAWES KAREN A","position":1,"cik":"0001261506","reported_name":"DAWES KAREN A","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Share Option (Right to Buy)","published_at":"2026-09-09T20:15:12.000Z","date":"2026-09-09","kind":"disposition_to_issuer","planned":false,"acquired":false,"shares":19197,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F2","text":"This Form 4 reports securities transacted in connection with the Agreement and Plan of Merger, dated September 29, 2025, as amended (the \"Merger Agreement\") by and among the Issuer, Beacon Topco, Inc. (\"Topco\"), a Delaware corporation and a direct wholly owned subsidiary of the Issuer, Cdog Merger Sub, Inc., a Delaware corporation and a direct wholly owned subsidiary of Topco, and Clywedog Therapeutics, Inc., a Delaware corporation. On September 9, 2026 (the \"Effective Time\"), in connection with the effectiveness of the scheme of arrangement under Part 26 of the United Kingdom Companies Act 2006 (the \"Scheme\") contemplated by the Merger Agreement, Topco acquired the entire issued share capital of the Issuer, resulting in the Issuer becoming a direct wholly owned subsidiary of Topco."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F4","text":"Pursuant to the Merger Agreement, at the Effective Time, each option to acquire Shares under the Issuer's equity plans that was outstanding as of immediately prior to the Effective Time ceased to represent a right to acquire Shares of the Issuer, and was converted into an option to acquire shares of Topco Common Stock and assumed by Topco on the same terms and conditions (including applicable vesting and exercisability conditions) as were applicable to such option immediately prior to the Effective Time."},{"field":"derivative.underlying","element":"underlyingSecurityTitle","label":"F1","text":"The Ordinary Shares may be represented by American Depositary Shares (\"ADSs\" and together with the Ordinary Shares, the \"Shares\"), each of which currently represents one Ordinary Share."}],"balance_after":0,"derivative":{"exercise_price":2.27,"expiration_date":"2033-05-11","underlying":"Ordinary Shares","underlying_shares":19197},"source":{"system":"sec-edgar","filing":"0001104659-26-106323","document":"tm2625057-1_4seq1.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":4,"url":"https://www.sec.gov/Archives/edgar/data/1828185/000110465926106323/tm2625057-1_4seq1.xml","form_type":"4"}},{"id":4613293,"issuer":{"id":9597,"kind":"organization","name":"Barinthus Biotherapeutics plc.","symbol":"BRNS"},"owners":[{"id":46694,"kind":"person","name":"DAWES KAREN A","position":1,"cik":"0001261506","reported_name":"DAWES KAREN A","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Share Option (Right to Buy)","published_at":"2026-09-09T20:15:12.000Z","date":"2026-09-09","kind":"disposition_to_issuer","planned":false,"acquired":false,"shares":18604,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F2","text":"This Form 4 reports securities transacted in connection with the Agreement and Plan of Merger, dated September 29, 2025, as amended (the \"Merger Agreement\") by and among the Issuer, Beacon Topco, Inc. (\"Topco\"), a Delaware corporation and a direct wholly owned subsidiary of the Issuer, Cdog Merger Sub, Inc., a Delaware corporation and a direct wholly owned subsidiary of Topco, and Clywedog Therapeutics, Inc., a Delaware corporation. On September 9, 2026 (the \"Effective Time\"), in connection with the effectiveness of the scheme of arrangement under Part 26 of the United Kingdom Companies Act 2006 (the \"Scheme\") contemplated by the Merger Agreement, Topco acquired the entire issued share capital of the Issuer, resulting in the Issuer becoming a direct wholly owned subsidiary of Topco."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F4","text":"Pursuant to the Merger Agreement, at the Effective Time, each option to acquire Shares under the Issuer's equity plans that was outstanding as of immediately prior to the Effective Time ceased to represent a right to acquire Shares of the Issuer, and was converted into an option to acquire shares of Topco Common Stock and assumed by Topco on the same terms and conditions (including applicable vesting and exercisability conditions) as were applicable to such option immediately prior to the Effective Time."},{"field":"derivative.underlying","element":"underlyingSecurityTitle","label":"F1","text":"The Ordinary Shares may be represented by American Depositary Shares (\"ADSs\" and together with the Ordinary Shares, the \"Shares\"), each of which currently represents one Ordinary Share."}],"balance_after":0,"derivative":{"exercise_price":4.27,"expiration_date":"2032-06-15","underlying":"Ordinary Shares","underlying_shares":18604},"source":{"system":"sec-edgar","filing":"0001104659-26-106323","document":"tm2625057-1_4seq1.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":3,"url":"https://www.sec.gov/Archives/edgar/data/1828185/000110465926106323/tm2625057-1_4seq1.xml","form_type":"4"}},{"id":4613292,"issuer":{"id":9597,"kind":"organization","name":"Barinthus Biotherapeutics plc.","symbol":"BRNS"},"owners":[{"id":46694,"kind":"person","name":"DAWES KAREN A","position":1,"cik":"0001261506","reported_name":"DAWES KAREN A","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Share Option (Right to Buy)","published_at":"2026-09-09T20:15:12.000Z","date":"2026-09-09","kind":"disposition_to_issuer","planned":false,"acquired":false,"shares":34328,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F2","text":"This Form 4 reports securities transacted in connection with the Agreement and Plan of Merger, dated September 29, 2025, as amended (the \"Merger Agreement\") by and among the Issuer, Beacon Topco, Inc. (\"Topco\"), a Delaware corporation and a direct wholly owned subsidiary of the Issuer, Cdog Merger Sub, Inc., a Delaware corporation and a direct wholly owned subsidiary of Topco, and Clywedog Therapeutics, Inc., a Delaware corporation. On September 9, 2026 (the \"Effective Time\"), in connection with the effectiveness of the scheme of arrangement under Part 26 of the United Kingdom Companies Act 2006 (the \"Scheme\") contemplated by the Merger Agreement, Topco acquired the entire issued share capital of the Issuer, resulting in the Issuer becoming a direct wholly owned subsidiary of Topco."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F4","text":"Pursuant to the Merger Agreement, at the Effective Time, each option to acquire Shares under the Issuer's equity plans that was outstanding as of immediately prior to the Effective Time ceased to represent a right to acquire Shares of the Issuer, and was converted into an option to acquire shares of Topco Common Stock and assumed by Topco on the same terms and conditions (including applicable vesting and exercisability conditions) as were applicable to such option immediately prior to the Effective Time."},{"field":"derivative.underlying","element":"underlyingSecurityTitle","label":"F1","text":"The Ordinary Shares may be represented by American Depositary Shares (\"ADSs\" and together with the Ordinary Shares, the \"Shares\"), each of which currently represents one Ordinary Share."}],"balance_after":0,"derivative":{"exercise_price":17,"expiration_date":"2031-05-01","underlying":"Ordinary Shares","underlying_shares":34328},"source":{"system":"sec-edgar","filing":"0001104659-26-106323","document":"tm2625057-1_4seq1.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1828185/000110465926106323/tm2625057-1_4seq1.xml","form_type":"4"}},{"id":4613291,"issuer":{"id":9597,"kind":"organization","name":"Barinthus Biotherapeutics plc.","symbol":"BRNS"},"owners":[{"id":46694,"kind":"person","name":"DAWES KAREN A","position":1,"cik":"0001261506","reported_name":"DAWES KAREN A","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Ordinary Shares","published_at":"2026-09-09T20:15:12.000Z","date":"2026-09-09","kind":"disposition_to_issuer","planned":false,"acquired":false,"shares":1700,"ownership":{"direct":true},"footnotes":[{"field":"security","element":"securityTitle","label":"F1","text":"The Ordinary Shares may be represented by American Depositary Shares (\"ADSs\" and together with the Ordinary Shares, the \"Shares\"), each of which currently represents one Ordinary Share."},{"field":"kind","element":"transactionCoding","label":"F2","text":"This Form 4 reports securities transacted in connection with the Agreement and Plan of Merger, dated September 29, 2025, as amended (the \"Merger Agreement\") by and among the Issuer, Beacon Topco, Inc. (\"Topco\"), a Delaware corporation and a direct wholly owned subsidiary of the Issuer, Cdog Merger Sub, Inc., a Delaware corporation and a direct wholly owned subsidiary of Topco, and Clywedog Therapeutics, Inc., a Delaware corporation. On September 9, 2026 (the \"Effective Time\"), in connection with the effectiveness of the scheme of arrangement under Part 26 of the United Kingdom Companies Act 2006 (the \"Scheme\") contemplated by the Merger Agreement, Topco acquired the entire issued share capital of the Issuer, resulting in the Issuer becoming a direct wholly owned subsidiary of Topco."},{"field":"shares","element":"transactionShares","label":"F3","text":"Pursuant to the Merger Agreement and in connection with the effectiveness of the Scheme, at the Effective Time, each Share of the Issuer was converted into the right to receive 0.111 shares of common stock, $0.0001 par value per share, of Topco (the \"Topco Common Stock\")."},{"field":"price","element":"transactionPricePerShare","label":"F3","text":"Pursuant to the Merger Agreement and in connection with the effectiveness of the Scheme, at the Effective Time, each Share of the Issuer was converted into the right to receive 0.111 shares of common stock, $0.0001 par value per share, of Topco (the \"Topco Common Stock\")."}],"balance_after":0,"source":{"system":"sec-edgar","filing":"0001104659-26-106323","document":"tm2625057-1_4seq1.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1828185/000110465926106323/tm2625057-1_4seq1.xml","form_type":"4"}},{"id":1114878,"issuer":{"id":9597,"kind":"organization","name":"Barinthus Biotherapeutics plc.","symbol":"BRNS"},"owners":[{"id":34812,"kind":"person","name":"Phillips Anne M.","position":1,"cik":"0001627680","reported_name":"Phillips Anne M.","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Share Option (Right to Buy)","published_at":"2025-06-11T21:15:31.000Z","date":"2025-06-10","kind":"grant","planned":false,"acquired":true,"shares":20174,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"The shares underlying this option shall vest in full on the earlier of (i) June 10, 2026 or (ii) the next annual meeting of shareholders of the Issuer, subject to the Reporting Person's continued service as a director through the applicable vesting date."},{"field":"derivative.underlying","element":"underlyingSecurityTitle","label":"F2","text":"The Ordinary Shares may be represented by American Depositary Shares, each of which currently represents one Ordinary Share."}],"balance_after":20174,"derivative":{"exercise_price":1,"expiration_date":"2035-06-10","underlying":"Ordinary Shares","underlying_shares":20174},"source":{"system":"sec-edgar","filing":"0001828185-25-000043","document":"wk-form4_1749676523.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1627680/000182818525000043/wk-form4_1749676523.xml","form_type":"4"}},{"id":1115161,"issuer":{"id":9597,"kind":"organization","name":"Barinthus Biotherapeutics plc.","symbol":"BRNS"},"owners":[{"id":78629,"kind":"person","name":"Hammacher Alex","position":1,"cik":"0001851633","reported_name":"Hammacher Alex","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Share Option (Right to Buy)","published_at":"2025-06-11T17:18:30.000Z","date":"2025-06-10","kind":"grant","planned":false,"acquired":true,"shares":20174,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"The shares underlying this option shall vest in full on the earlier of (i) June 10, 2026 or (ii) the next annual meeting of shareholders of the Issuer, subject to the Reporting Person's continued service as a director through the applicable vesting date."},{"field":"derivative.underlying","element":"underlyingSecurityTitle","label":"F2","text":"The Ordinary Shares may be represented by American Depositary Shares, each of which currently represents one Ordinary Share."}],"balance_after":20174,"derivative":{"exercise_price":1,"expiration_date":"2035-06-10","underlying":"Ordinary Shares","underlying_shares":20174},"source":{"system":"sec-edgar","filing":"0001828185-25-000049","document":"wk-form4_1749676703.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1851633/000182818525000049/wk-form4_1749676703.xml","form_type":"4"}},{"id":1115159,"issuer":{"id":9597,"kind":"organization","name":"Barinthus Biotherapeutics plc.","symbol":"BRNS"},"owners":[{"id":78627,"kind":"person","name":"Wright Robin","position":1,"cik":"0001851640","reported_name":"Wright Robin","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Share Option (Right to Buy)","published_at":"2025-06-11T17:17:38.000Z","date":"2025-06-10","kind":"grant","planned":false,"acquired":true,"shares":20174,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"The shares underlying this option shall vest in full on the earlier of (i) June 10, 2026 or (ii) the next annual meeting of shareholders of the Issuer, subject to the Reporting Person's continued service as a director through the applicable vesting date."},{"field":"derivative.underlying","element":"underlyingSecurityTitle","label":"F2","text":"The Ordinary Shares may be represented by American Depositary Shares, each of which currently represents one Ordinary Share."}],"balance_after":20174,"derivative":{"exercise_price":1,"expiration_date":"2035-06-10","underlying":"Ordinary Shares","underlying_shares":20174},"source":{"system":"sec-edgar","filing":"0001828185-25-000047","document":"wk-form4_1749676649.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1851640/000182818525000047/wk-form4_1749676649.xml","form_type":"4"}},{"id":1115160,"issuer":{"id":9597,"kind":"organization","name":"Barinthus Biotherapeutics plc.","symbol":"BRNS"},"owners":[{"id":78628,"kind":"person","name":"Morgon Pierre A.","position":1,"cik":"0001851636","reported_name":"Morgon Pierre A.","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Share Option (Right to Buy)","published_at":"2025-06-11T17:16:31.000Z","date":"2025-06-10","kind":"grant","planned":false,"acquired":true,"shares":20174,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"The shares underlying this option shall vest in full on the earlier of (i) June 10, 2026 or (ii) the next annual meeting of shareholders of the Issuer, subject to the Reporting Person's continued service as a director through the applicable vesting date."},{"field":"derivative.underlying","element":"underlyingSecurityTitle","label":"F2","text":"The Ordinary Shares may be represented by American Depositary Shares, each of which currently represents one Ordinary Share."}],"balance_after":20174,"derivative":{"exercise_price":1,"expiration_date":"2035-06-10","underlying":"Ordinary Shares","underlying_shares":20174},"source":{"system":"sec-edgar","filing":"0001828185-25-000045","document":"wk-form4_1749676583.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1851636/000182818525000045/wk-form4_1749676583.xml","form_type":"4"}},{"id":1115164,"issuer":{"id":9597,"kind":"organization","name":"Barinthus Biotherapeutics plc.","symbol":"BRNS"},"owners":[{"id":78630,"kind":"person","name":"Scheeren Joseph","position":1,"cik":"0001852070","reported_name":"Scheeren Joseph","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Share Option (Right to Buy)","published_at":"2025-06-11T17:13:23.000Z","date":"2025-06-10","kind":"grant","planned":false,"acquired":true,"shares":20174,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"The shares underlying this option shall vest in full on the earlier of (i) June 10, 2026 or (ii) the next annual meeting of shareholders of the Issuer, subject to the Reporting Person's continued service as a director through the applicable vesting date."},{"field":"derivative.underlying","element":"underlyingSecurityTitle","label":"F2","text":"The Ordinary Shares may be represented by American Depositary Shares, each of which currently represents one Ordinary Share."}],"balance_after":20174,"derivative":{"exercise_price":1,"expiration_date":"2035-06-10","underlying":"Ordinary Shares","underlying_shares":20174},"source":{"system":"sec-edgar","filing":"0001828185-25-000041","document":"wk-form4_1749676396.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1852070/000182818525000041/wk-form4_1749676396.xml","form_type":"4"}},{"id":1114765,"issuer":{"id":9597,"kind":"organization","name":"Barinthus Biotherapeutics plc.","symbol":"BRNS"},"owners":[{"id":46694,"kind":"person","name":"DAWES KAREN A","position":1,"cik":"0001261506","reported_name":"DAWES KAREN A","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Share Option (Right to Buy)","published_at":"2025-06-11T17:10:29.000Z","date":"2025-06-10","kind":"grant","planned":false,"acquired":true,"shares":20174,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"The shares underlying this option shall vest in full on the earlier of (i) June 10, 2026 or (ii) the next annual meeting of shareholders of the Issuer, subject to the Reporting Person's continued service as a director through the applicable vesting date."},{"field":"derivative.underlying","element":"underlyingSecurityTitle","label":"F2","text":"The Ordinary Shares may be represented by American Depositary Shares, each of which currently represents one Ordinary Share."}],"balance_after":20174,"derivative":{"exercise_price":1,"expiration_date":"2035-06-10","underlying":"Ordinary Shares","underlying_shares":20174},"source":{"system":"sec-edgar","filing":"0001828185-25-000039","document":"wk-form4_1749676222.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1261506/000182818525000039/wk-form4_1749676222.xml","form_type":"4"}},{"id":1281309,"issuer":{"id":9597,"kind":"organization","name":"Barinthus Biotherapeutics plc.","symbol":"BRNS"},"owners":[{"id":83544,"kind":"person","name":"Brown Gemma","position":1,"cik":"0001947293","reported_name":"Brown Gemma","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Financial Officer"}}],"security":"Share Option (Right to Buy)","published_at":"2025-02-05T21:24:43.000Z","date":"2025-02-03","kind":"grant","planned":false,"acquired":true,"shares":160000,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"The shares underlying this option shall vest and become exercisable in three equal annual installments, with the first installment vesting on February 3, 2026."},{"field":"derivative.underlying","element":"underlyingSecurityTitle","label":"F2","text":"The Ordinary Shares may be represented by American Depositary Shares, each of which currently represents one Ordinary Share."}],"balance_after":160000,"derivative":{"exercise_price":1,"expiration_date":"2035-02-03","underlying":"Ordinary Shares","underlying_shares":160000},"source":{"system":"sec-edgar","filing":"0001828185-25-000012","document":"wk-form4_1738790675.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1828185/000182818525000012/wk-form4_1738790675.xml","form_type":"4"}},{"id":1281384,"issuer":{"id":9597,"kind":"organization","name":"Barinthus Biotherapeutics plc.","symbol":"BRNS"},"owners":[{"id":38019,"kind":"person","name":"Enright William","position":1,"cik":"0001705564","reported_name":"Enright William","relationship":{"director":true,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Executive Officer"}}],"security":"Share Option (Right to Buy)","published_at":"2025-02-05T21:24:31.000Z","date":"2025-02-03","kind":"grant","planned":false,"acquired":true,"shares":600000,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"The shares underlying this option shall vest and become exercisable in three equal annual installments, with the first installment vesting on February 3, 2026."},{"field":"derivative.underlying","element":"underlyingSecurityTitle","label":"F2","text":"The Ordinary Shares may be represented by American Depositary Shares, each of which currently represents one Ordinary Share."}],"balance_after":600000,"derivative":{"exercise_price":1,"expiration_date":"2035-02-03","underlying":"Ordinary Shares","underlying_shares":600000},"source":{"system":"sec-edgar","filing":"0001828185-25-000011","document":"wk-form4_1738790662.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1705564/000182818525000011/wk-form4_1738790662.xml","form_type":"4"}},{"id":1282090,"issuer":{"id":9597,"kind":"organization","name":"Barinthus Biotherapeutics plc.","symbol":"BRNS"},"owners":[{"id":83560,"kind":"person","name":"Griffiths Graham","position":1,"cik":"0001851630","reported_name":"Griffiths Graham","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Business Officer"}}],"security":"Share Option (Right to Buy)","published_at":"2025-02-05T16:24:18.000Z","date":"2025-02-03","kind":"grant","planned":false,"acquired":true,"shares":200000,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"The shares underlying this option shall vest and become exercisable in three equal annual installments, with the first installment vesting on February 3, 2026."},{"field":"derivative.underlying","element":"underlyingSecurityTitle","label":"F2","text":"The Ordinary Shares may be represented by American Depositary Shares, each of which currently represents one Ordinary Share."}],"balance_after":200000,"derivative":{"exercise_price":1,"expiration_date":"2035-02-03","underlying":"Ordinary Shares","underlying_shares":200000},"source":{"system":"sec-edgar","filing":"0001828185-25-000010","document":"wk-form4_1738790649.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1851630/000182818525000010/wk-form4_1738790649.xml","form_type":"4"}},{"id":1282294,"issuer":{"id":9597,"kind":"organization","name":"Barinthus Biotherapeutics plc.","symbol":"BRNS"},"owners":[{"id":83565,"kind":"person","name":"Hooftman Leon","position":1,"cik":"0002027157","reported_name":"Hooftman Leon","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Medical Officer"}}],"security":"Share Option (Right to Buy)","published_at":"2025-02-05T16:24:06.000Z","date":"2025-02-03","kind":"grant","planned":false,"acquired":true,"shares":140000,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"The shares underlying this option shall vest and become exercisable in three equal annual installments, with the first installment vesting on February 3, 2026."},{"field":"derivative.underlying","element":"underlyingSecurityTitle","label":"F2","text":"The Ordinary Shares may be represented by American Depositary Shares, each of which currently represents one Ordinary Share."}],"balance_after":140000,"derivative":{"exercise_price":1,"expiration_date":"2035-02-03","underlying":"Ordinary Shares","underlying_shares":140000},"source":{"system":"sec-edgar","filing":"0001828185-25-000009","document":"wk-form4_1738790637.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/2027157/000182818525000009/wk-form4_1738790637.xml","form_type":"4"}},{"id":1475862,"issuer":{"id":9597,"kind":"organization","name":"Barinthus Biotherapeutics plc.","symbol":"BRNS"},"owners":[{"id":83565,"kind":"person","name":"Hooftman Leon","position":1,"cik":"0002027157","reported_name":"Hooftman Leon","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Medical Officer"}}],"security":"Share Option (Right to Buy)","published_at":"2024-06-18T16:07:12.000Z","date":"2024-06-03","kind":"grant","planned":false,"acquired":true,"shares":195166,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"The shares underlying this option shall vest and become exercisable in three equal annual installments, with the first installment vesting on June 3, 2025."},{"field":"derivative.underlying","element":"underlyingSecurityTitle","label":"F2","text":"The Ordinary Shares may be represented by American Depositary Shares, each of which currently represents one Ordinary Share."}],"balance_after":195166,"derivative":{"exercise_price":2,"expiration_date":"2034-06-03","underlying":"Ordinary Shares","underlying_shares":195166},"source":{"system":"sec-edgar","filing":"0001104659-24-072802","document":"tm2417524-2_4seq1.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/2027157/000110465924072802/tm2417524-2_4seq1.xml","form_type":"4"}},{"id":1517448,"issuer":{"id":9597,"kind":"organization","name":"Barinthus Biotherapeutics plc.","symbol":"BRNS"},"owners":[{"id":34812,"kind":"person","name":"Phillips Anne M.","position":1,"cik":"0001627680","reported_name":"Phillips Anne M.","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Share Option (Right to Buy)","published_at":"2024-05-14T20:19:12.000Z","date":"2024-05-10","kind":"grant","planned":false,"acquired":true,"shares":19516,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"The shares underlying this option shall vest in full on the earlier of (i) May 10, 2025 or (ii) the next annual meeting of shareholders of the Issuer, subject to the Reporting Person's continued service as a director through the applicable vesting date."},{"field":"derivative.underlying","element":"underlyingSecurityTitle","label":"F2","text":"The Ordinary Shares may be represented by American Depositary Shares, each of which currently represents one Ordinary Share."}],"balance_after":19516,"derivative":{"exercise_price":2.34,"expiration_date":"2034-05-10","underlying":"Ordinary Shares","underlying_shares":19516},"source":{"system":"sec-edgar","filing":"0001828185-24-000054","document":"wk-form4_1715717940.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1627680/000182818524000054/wk-form4_1715717940.xml","form_type":"4"}},{"id":1517254,"issuer":{"id":9597,"kind":"organization","name":"Barinthus Biotherapeutics plc.","symbol":"BRNS"},"owners":[{"id":46694,"kind":"person","name":"DAWES KAREN A","position":1,"cik":"0001261506","reported_name":"DAWES KAREN A","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Share Option (Right to Buy)","published_at":"2024-05-14T16:23:15.000Z","date":"2024-05-10","kind":"grant","planned":false,"acquired":true,"shares":19516,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"The shares underlying this option shall vest in full on the earlier of (i) May 10, 2025 or (ii) the next annual meeting of shareholders of the Issuer, subject to the Reporting Person's continued service as a director through the applicable vesting date."},{"field":"derivative.underlying","element":"underlyingSecurityTitle","label":"F2","text":"The Ordinary Shares may be represented by American Depositary Shares, each of which currently represents one Ordinary Share."}],"balance_after":19516,"derivative":{"exercise_price":2.34,"expiration_date":"2034-05-10","underlying":"Ordinary Shares","underlying_shares":19516},"source":{"system":"sec-edgar","filing":"0001828185-24-000058","document":"wk-form4_1715718176.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1261506/000182818524000058/wk-form4_1715718176.xml","form_type":"4"}},{"id":1517680,"issuer":{"id":9597,"kind":"organization","name":"Barinthus Biotherapeutics plc.","symbol":"BRNS"},"owners":[{"id":78630,"kind":"person","name":"Scheeren Joseph","position":1,"cik":"0001852070","reported_name":"Scheeren Joseph","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Share Option (Right to Buy)","published_at":"2024-05-14T16:21:16.000Z","date":"2024-05-10","kind":"grant","planned":false,"acquired":true,"shares":19516,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"The shares underlying this option shall vest in full on the earlier of (i) May 10, 2025 or (ii) the next annual meeting of shareholders of the Issuer, subject to the Reporting Person's continued service as a director through the applicable vesting date."},{"field":"derivative.underlying","element":"underlyingSecurityTitle","label":"F2","text":"The Ordinary Shares may be represented by American Depositary Shares, each of which currently represents one Ordinary Share."}],"balance_after":19516,"derivative":{"exercise_price":2.34,"expiration_date":"2034-05-10","underlying":"Ordinary Shares","underlying_shares":19516},"source":{"system":"sec-edgar","filing":"0001828185-24-000056","document":"wk-form4_1715718060.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1852070/000182818524000056/wk-form4_1715718060.xml","form_type":"4"}},{"id":1517676,"issuer":{"id":9597,"kind":"organization","name":"Barinthus Biotherapeutics plc.","symbol":"BRNS"},"owners":[{"id":78629,"kind":"person","name":"Hammacher Alex","position":1,"cik":"0001851633","reported_name":"Hammacher Alex","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Share Option (Right to Buy)","published_at":"2024-05-14T16:17:25.000Z","date":"2024-05-10","kind":"grant","planned":false,"acquired":true,"shares":19516,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"The shares underlying this option shall vest in full on the earlier of (i) May 10, 2025 or (ii) the next annual meeting of shareholders of the Issuer, subject to the Reporting Person's continued service as a director through the applicable vesting date."},{"field":"derivative.underlying","element":"underlyingSecurityTitle","label":"F2","text":"The Ordinary Shares may be represented by American Depositary Shares, each of which currently represents one Ordinary Share."}],"balance_after":19516,"derivative":{"exercise_price":2.34,"expiration_date":"2034-05-10","underlying":"Ordinary Shares","underlying_shares":19516},"source":{"system":"sec-edgar","filing":"0001828185-24-000052","document":"wk-form4_1715717828.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1851633/000182818524000052/wk-form4_1715717828.xml","form_type":"4"}},{"id":1517675,"issuer":{"id":9597,"kind":"organization","name":"Barinthus Biotherapeutics plc.","symbol":"BRNS"},"owners":[{"id":78628,"kind":"person","name":"Morgon Pierre A.","position":1,"cik":"0001851636","reported_name":"Morgon Pierre A.","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Share Option (Right to Buy)","published_at":"2024-05-14T16:15:39.000Z","date":"2024-05-10","kind":"grant","planned":false,"acquired":true,"shares":19516,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"The shares underlying this option shall vest in full on the earlier of (i) May 10, 2025 or (ii) the next annual meeting of shareholders of the Issuer, subject to the Reporting Person's continued service as a director through the applicable vesting date."},{"field":"derivative.underlying","element":"underlyingSecurityTitle","label":"F2","text":"The Ordinary Shares may be represented by American Depositary Shares, each of which currently represents one Ordinary Share."}],"balance_after":19516,"derivative":{"exercise_price":2.34,"expiration_date":"2034-05-10","underlying":"Ordinary Shares","underlying_shares":19516},"source":{"system":"sec-edgar","filing":"0001828185-24-000050","document":"wk-form4_1715717728.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1851636/000182818524000050/wk-form4_1715717728.xml","form_type":"4"}},{"id":1517674,"issuer":{"id":9597,"kind":"organization","name":"Barinthus Biotherapeutics plc.","symbol":"BRNS"},"owners":[{"id":78627,"kind":"person","name":"Wright Robin","position":1,"cik":"0001851640","reported_name":"Wright Robin","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Share Option (Right to Buy)","published_at":"2024-05-14T16:13:44.000Z","date":"2024-05-10","kind":"grant","planned":false,"acquired":true,"shares":19516,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"The shares underlying this option shall vest in full on the earlier of (i) May 10, 2025 or (ii) the next annual meeting of shareholders of the Issuer, subject to the Reporting Person's continued service as a director through the applicable vesting date."},{"field":"derivative.underlying","element":"underlyingSecurityTitle","label":"F2","text":"The Ordinary Shares may be represented by American Depositary Shares, each of which currently represents one Ordinary Share."}],"balance_after":19516,"derivative":{"exercise_price":2.34,"expiration_date":"2034-05-10","underlying":"Ordinary Shares","underlying_shares":19516},"source":{"system":"sec-edgar","filing":"0001828185-24-000048","document":"wk-form4_1715717606.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1851640/000182818524000048/wk-form4_1715717606.xml","form_type":"4"}},{"id":1686794,"issuer":{"id":9597,"kind":"organization","name":"Barinthus Biotherapeutics plc.","symbol":"BRNS"},"owners":[{"id":95453,"kind":"person","name":"Pelletier Nadege","position":1,"cik":"0001965689","reported_name":"Pelletier Nadege","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Scientific Officer"}}],"security":"Share Option (Right to Buy)","published_at":"2024-01-04T13:56:29.000Z","date":"2024-01-02","kind":"grant","planned":false,"acquired":true,"shares":105000,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"The shares underlying this option shall vest and become exercisable in three equal annual installments, with the first installment vesting on January 2, 2025."},{"field":"derivative.underlying","element":"underlyingSecurityTitle","label":"F2","text":"The Ordinary Shares may be represented by American Depositary Shares, each of which currently represents one Ordinary Share."}],"balance_after":105000,"derivative":{"exercise_price":3.7,"expiration_date":"2034-01-02","underlying":"Ordinary Shares","underlying_shares":105000},"source":{"system":"sec-edgar","filing":"0001104659-24-001167","document":"tm241766-4_4seq1.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1828185/000110465924001167/tm241766-4_4seq1.xml","form_type":"4"}},{"id":1686876,"issuer":{"id":9597,"kind":"organization","name":"Barinthus Biotherapeutics plc.","symbol":"BRNS"},"owners":[{"id":38019,"kind":"person","name":"Enright William","position":1,"cik":"0001705564","reported_name":"Enright William","relationship":{"director":true,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Executive Officer"}}],"security":"Share Option (Right to Buy)","published_at":"2024-01-04T13:54:01.000Z","date":"2024-01-02","kind":"grant","planned":false,"acquired":true,"shares":443981,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"The shares underlying this option shall vest and become exercisable in three equal annual installments, with the first installment vesting on January 2, 2025."},{"field":"derivative.underlying","element":"underlyingSecurityTitle","label":"F2","text":"The Ordinary Shares may be represented by American Depositary Shares, each of which currently represents one Ordinary Share."}],"balance_after":443981,"derivative":{"exercise_price":3.7,"expiration_date":"2034-01-02","underlying":"Ordinary Shares","underlying_shares":443981},"source":{"system":"sec-edgar","filing":"0001104659-24-001165","document":"tm241766-2_4seq1.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1705564/000110465924001165/tm241766-2_4seq1.xml","form_type":"4"}},{"id":1686792,"issuer":{"id":9597,"kind":"organization","name":"Barinthus Biotherapeutics plc.","symbol":"BRNS"},"owners":[{"id":83544,"kind":"person","name":"Brown Gemma","position":1,"cik":"0001947293","reported_name":"Brown Gemma","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Financial Officer"}}],"security":"Share Option (Right to Buy)","published_at":"2024-01-04T13:52:44.000Z","date":"2024-01-02","kind":"grant","planned":false,"acquired":true,"shares":193000,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"The shares underlying this option shall vest and become exercisable in three equal annual installments, with the first installment vesting on January 2, 2025."},{"field":"derivative.underlying","element":"underlyingSecurityTitle","label":"F2","text":"The Ordinary Shares may be represented by American Depositary Shares, each of which currently represents one Ordinary Share."}],"balance_after":193000,"derivative":{"exercise_price":3.7,"expiration_date":"2034-01-02","underlying":"Ordinary Shares","underlying_shares":193000},"source":{"system":"sec-edgar","filing":"0001104659-24-001164","document":"tm241766-1_4seq1.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1828185/000110465924001164/tm241766-1_4seq1.xml","form_type":"4"}},{"id":1688142,"issuer":{"id":9597,"kind":"organization","name":"Barinthus Biotherapeutics plc.","symbol":"BRNS"},"owners":[{"id":83560,"kind":"person","name":"Griffiths Graham","position":1,"cik":"0001851630","reported_name":"Griffiths Graham","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Business Officer"}}],"security":"Share Option (Right to Buy)","published_at":"2024-01-04T08:55:03.000Z","date":"2024-01-02","kind":"grant","planned":false,"acquired":true,"shares":96500,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"The shares underlying this option shall vest and become exercisable in three equal annual installments, with the first installment vesting on January 2, 2025."},{"field":"derivative.underlying","element":"underlyingSecurityTitle","label":"F2","text":"The Ordinary Shares may be represented by American Depositary Shares, each of which currently represents one Ordinary Share."}],"balance_after":96500,"derivative":{"exercise_price":3.7,"expiration_date":"2034-01-02","underlying":"Ordinary Shares","underlying_shares":96500},"source":{"system":"sec-edgar","filing":"0001104659-24-001166","document":"tm241766-3_4seq1.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1851630/000110465924001166/tm241766-3_4seq1.xml","form_type":"4"}},{"id":1842779,"issuer":{"id":9597,"kind":"organization","name":"Barinthus Biotherapeutics plc.","symbol":"BRNS"},"owners":[{"id":78630,"kind":"person","name":"Scheeren Joseph","position":1,"cik":"0001852070","reported_name":"Scheeren Joseph","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Ordinary Shares","published_at":"2023-06-28T07:52:00.000Z","date":"2023-06-26","kind":"purchase","planned":false,"acquired":true,"shares":10000,"price":2.44,"value":24400.0,"ownership":{"direct":true},"footnotes":[{"field":"security","element":"securityTitle","label":"F1","text":"The Ordinary Shares may be represented by American Depositary Shares, each of which currently represents one Ordinary Share."}],"balance_after":23000,"source":{"system":"sec-edgar","filing":"0001104659-23-075562","document":"tm2319828-1_4seq1.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1852070/000110465923075562/tm2319828-1_4seq1.xml","form_type":"4"}},{"id":1872189,"issuer":{"id":9597,"kind":"organization","name":"Barinthus Biotherapeutics plc.","symbol":"BRNS"},"owners":[{"id":78627,"kind":"person","name":"Wright Robin","position":1,"cik":"0001851640","reported_name":"Wright Robin","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Ordinary Shares","published_at":"2023-06-01T16:33:08.000Z","date":"2023-05-25","kind":"purchase","planned":false,"acquired":true,"shares":13750,"price":2.6627,"value":36612.125,"ownership":{"direct":true},"footnotes":[{"field":"security","element":"securityTitle","label":"F1","text":"The Ordinary Shares may be represented by American Depositary Shares, each of which currently represents one Ordinary Share."},{"field":"price","element":"transactionPricePerShare","label":"F2","text":"The price reported in Column 4 is a weighted average price. These shares were purchased in multiple transactions at prices ranging from $2.48 to $2.70, inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares purchased at each separate price within the range."}],"balance_after":48256,"source":{"system":"sec-edgar","filing":"0001104659-23-067081","document":"tm2317604-1_4seq1.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1851640/000110465923067081/tm2317604-1_4seq1.xml","form_type":"4"}},{"id":1895011,"issuer":{"id":9597,"kind":"organization","name":"Barinthus Biotherapeutics plc.","symbol":"BRNS"},"owners":[{"id":34812,"kind":"person","name":"Phillips Anne M.","position":1,"cik":"0001627680","reported_name":"Phillips Anne M.","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Share Option (Right to Buy)","published_at":"2023-05-12T20:07:00.000Z","date":"2023-05-11","kind":"grant","planned":false,"acquired":true,"shares":19197,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"The shares underlying this option shall vest in full on the earlier of (i) May 11, 2024 or (ii) the next annual meeting of shareholders of the Issuer, subject to the Reporting Person's continued service as a director through the applicable vesting date."},{"field":"derivative.underlying","element":"underlyingSecurityTitle","label":"F2","text":"The Ordinary Shares may be represented by American Depositary Shares, each of which currently represents one Ordinary Share."}],"balance_after":19197,"derivative":{"exercise_price":2.27,"expiration_date":"2033-05-11","underlying":"Ordinary Shares","underlying_shares":19197},"source":{"system":"sec-edgar","filing":"0001104659-23-059726","document":"tm2315647-4_4seq1.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1627680/000110465923059726/tm2315647-4_4seq1.xml","form_type":"4"}},{"id":1895242,"issuer":{"id":9597,"kind":"organization","name":"Barinthus Biotherapeutics plc.","symbol":"BRNS"},"owners":[{"id":78627,"kind":"person","name":"Wright Robin","position":1,"cik":"0001851640","reported_name":"Wright Robin","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Share Option (Right to Buy)","published_at":"2023-05-12T16:07:27.000Z","date":"2023-05-11","kind":"grant","planned":false,"acquired":true,"shares":19197,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"The shares underlying this option shall vest in full on the earlier of (i) May 11, 2024 or (ii) the next annual meeting of shareholders of the Issuer, subject to the Reporting Person's continued service as a director through the applicable vesting date."},{"field":"derivative.underlying","element":"underlyingSecurityTitle","label":"F2","text":"The Ordinary Shares may be represented by American Depositary Shares, each of which currently represents one Ordinary Share."}],"balance_after":19197,"derivative":{"exercise_price":2.27,"expiration_date":"2033-05-11","underlying":"Ordinary Shares","underlying_shares":19197},"source":{"system":"sec-edgar","filing":"0001104659-23-059729","document":"tm2315647-6_4seq1.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1851640/000110465923059729/tm2315647-6_4seq1.xml","form_type":"4"}},{"id":1895252,"issuer":{"id":9597,"kind":"organization","name":"Barinthus Biotherapeutics plc.","symbol":"BRNS"},"owners":[{"id":78630,"kind":"person","name":"Scheeren Joseph","position":1,"cik":"0001852070","reported_name":"Scheeren Joseph","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Share Option (Right to Buy)","published_at":"2023-05-12T16:07:18.000Z","date":"2023-05-11","kind":"grant","planned":false,"acquired":true,"shares":19197,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"The shares underlying this option shall vest in full on the earlier of (i) May 11, 2024 or (ii) the next annual meeting of shareholders of the Issuer, subject to the Reporting Person's continued service as a director through the applicable vesting date."},{"field":"derivative.underlying","element":"underlyingSecurityTitle","label":"F2","text":"The Ordinary Shares may be represented by American Depositary Shares, each of which currently represents one Ordinary Share."}],"balance_after":19197,"derivative":{"exercise_price":2.27,"expiration_date":"2033-05-11","underlying":"Ordinary Shares","underlying_shares":19197},"source":{"system":"sec-edgar","filing":"0001104659-23-059727","document":"tm2315647-5_4seq1.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1852070/000110465923059727/tm2315647-5_4seq1.xml","form_type":"4"}},{"id":1895243,"issuer":{"id":9597,"kind":"organization","name":"Barinthus Biotherapeutics plc.","symbol":"BRNS"},"owners":[{"id":78628,"kind":"person","name":"Morgon Pierre A.","position":1,"cik":"0001851636","reported_name":"Morgon Pierre A.","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Share Option (Right to Buy)","published_at":"2023-05-12T16:06:07.000Z","date":"2023-05-11","kind":"grant","planned":false,"acquired":true,"shares":19197,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"The shares underlying this option shall vest in full on the earlier of (i) May 11, 2024 or (ii) the next annual meeting of shareholders of the Issuer, subject to the Reporting Person's continued service as a director through the applicable vesting date."},{"field":"derivative.underlying","element":"underlyingSecurityTitle","label":"F2","text":"The Ordinary Shares may be represented by American Depositary Shares, each of which currently represents one Ordinary Share."}],"balance_after":19197,"derivative":{"exercise_price":2.27,"expiration_date":"2033-05-11","underlying":"Ordinary Shares","underlying_shares":19197},"source":{"system":"sec-edgar","filing":"0001104659-23-059722","document":"tm2315647-3_4seq1.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1851636/000110465923059722/tm2315647-3_4seq1.xml","form_type":"4"}},{"id":1895244,"issuer":{"id":9597,"kind":"organization","name":"Barinthus Biotherapeutics plc.","symbol":"BRNS"},"owners":[{"id":78629,"kind":"person","name":"Hammacher Alex","position":1,"cik":"0001851633","reported_name":"Hammacher Alex","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Share Option (Right to Buy)","published_at":"2023-05-12T16:05:28.000Z","date":"2023-05-11","kind":"grant","planned":false,"acquired":true,"shares":19197,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"The shares underlying this option shall vest in full on the earlier of (i) May 11, 2024 or (ii) the next annual meeting of shareholders of the Issuer, subject to the Reporting Person's continued service as a director through the applicable vesting date."},{"field":"derivative.underlying","element":"underlyingSecurityTitle","label":"F2","text":"The Ordinary Shares may be represented by American Depositary Shares, each of which currently represents one Ordinary Share."}],"balance_after":19197,"derivative":{"exercise_price":2.27,"expiration_date":"2033-05-11","underlying":"Ordinary Shares","underlying_shares":19197},"source":{"system":"sec-edgar","filing":"0001104659-23-059716","document":"tm2315647-2_4seq1.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1851633/000110465923059716/tm2315647-2_4seq1.xml","form_type":"4"}},{"id":1894853,"issuer":{"id":9597,"kind":"organization","name":"Barinthus Biotherapeutics plc.","symbol":"BRNS"},"owners":[{"id":46694,"kind":"person","name":"DAWES KAREN A","position":1,"cik":"0001261506","reported_name":"DAWES KAREN A","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Share Option (Right to Buy)","published_at":"2023-05-12T16:05:17.000Z","date":"2023-05-11","kind":"grant","planned":false,"acquired":true,"shares":19197,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"The shares underlying this option shall vest in full on the earlier of (i) May 11, 2024 or (ii) the next annual meeting of shareholders of the Issuer, subject to the Reporting Person's continued service as a director through the applicable vesting date."},{"field":"derivative.underlying","element":"underlyingSecurityTitle","label":"F2","text":"The Ordinary Shares may be represented by American Depositary Shares, each of which currently represents one Ordinary Share."}],"balance_after":19197,"derivative":{"exercise_price":2.27,"expiration_date":"2033-05-11","underlying":"Ordinary Shares","underlying_shares":19197},"source":{"system":"sec-edgar","filing":"0001104659-23-059712","document":"tm2315647-1_4seq1.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1261506/000110465923059712/tm2315647-1_4seq1.xml","form_type":"4"}},{"id":1935471,"issuer":{"id":9597,"kind":"organization","name":"Barinthus Biotherapeutics plc.","symbol":"BRNS"},"owners":[{"id":38019,"kind":"person","name":"Enright William","position":1,"cik":"0001705564","reported_name":"Enright William","relationship":{"director":true,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Executive Officer"}}],"security":"Ordinary Shares","published_at":"2023-03-29T20:41:00.000Z","date":"2023-03-27","kind":"sale","planned":false,"acquired":false,"shares":15000,"price":2.4199,"value":36298.5,"ownership":{"direct":false,"nature":"By Trust"},"footnotes":[{"field":"security","element":"securityTitle","label":"F1","text":"The Ordinary Shares may be represented by American Depositary Shares, each of which currently represents one Ordinary Share."},{"field":"price","element":"transactionPricePerShare","label":"F2","text":"The price reported in column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $2.40 - $2.47. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F3","text":"Shares held by William J Enright TR UA Dated 03/04/2021 Enright Family 2021 Irrevocable Trust, of which the Reporting Person serves as trustee. The Reporting Person disclaims beneficial ownership of the shares held by such trust for purposes of Section 16 of the Exchange Act, except to the extent of his pecuniary interest therein, if any."}],"balance_after":728454,"source":{"system":"sec-edgar","filing":"0001104659-23-038357","document":"tm2310913-1_4seq1.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1705564/000110465923038357/tm2310913-1_4seq1.xml","form_type":"4"}},{"id":1935850,"issuer":{"id":9597,"kind":"organization","name":"Barinthus Biotherapeutics plc.","symbol":"BRNS"},"owners":[{"id":115023,"kind":"person","name":"Marshall Margaret","position":1,"cik":"0001851634","reported_name":"Marshall Margaret","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Medical Officer"}}],"security":"Share Option (Right to Buy)","published_at":"2023-03-29T16:45:38.000Z","date":"2023-01-03","kind":"grant","planned":false,"acquired":true,"shares":60000,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F2","text":"This option shall vest and become exercisable in three equal annual installments, with the first installment vesting on January 3, 2024."},{"field":"derivative.underlying","element":"underlyingSecurityTitle","label":"F1","text":"The Ordinary Shares may be represented by American Depositary Shares, each of which currently represents one Ordinary Share."}],"balance_after":60000,"derivative":{"exercise_price":2.4,"expiration_date":"2033-01-03","underlying":"Ordinary Shares","underlying_shares":60000},"source":{"system":"sec-edgar","filing":"0001104659-23-038365","document":"tm2310913-3_4seq1.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1851634/000110465923038365/tm2310913-3_4seq1.xml","form_type":"4"}},{"id":1935849,"issuer":{"id":9597,"kind":"organization","name":"Barinthus Biotherapeutics plc.","symbol":"BRNS"},"owners":[{"id":115022,"kind":"person","name":"Evans Thomas George","position":1,"cik":"0001851686","reported_name":"Evans Thomas George","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Fmr Chief Scientific Officer"}}],"security":"Share Option (Right to Buy)","published_at":"2023-03-29T16:43:22.000Z","date":"2023-01-03","kind":"grant","planned":false,"acquired":true,"shares":125000,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F2","text":"This option shall vest and become exercisable in three equal annual installments, with the first installment vesting on January 3, 2024."},{"field":"derivative.underlying","element":"underlyingSecurityTitle","label":"F1","text":"The Ordinary Shares may be represented by American Depositary Shares, each of which currently represents one Ordinary Share."}],"balance_after":125000,"derivative":{"exercise_price":2.4,"expiration_date":"2033-01-03","underlying":"Ordinary Shares","underlying_shares":125000},"source":{"system":"sec-edgar","filing":"0001104659-23-038362","document":"tm2310913-2_4seq1.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1851686/000110465923038362/tm2310913-2_4seq1.xml","form_type":"4"}},{"id":1992208,"issuer":{"id":9597,"kind":"organization","name":"Barinthus Biotherapeutics plc.","symbol":"BRNS"},"owners":[{"id":95453,"kind":"person","name":"Pelletier Nadege","position":1,"cik":"0001965689","reported_name":"Pelletier Nadege","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Scientific Officer"}}],"security":"Share Option (Right to Buy)","published_at":"2023-02-24T22:25:16.000Z","date":"2023-02-01","kind":"grant","acquired":true,"shares":485000,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F2","text":"This option shall vest and become exercisable in three equal annual installments, with the first installment vesting on February 1, 2024."},{"field":"derivative.underlying","element":"underlyingSecurityTitle","label":"F1","text":"The Ordinary Shares may be represented by American Depositary Shares, each of which currently represents one Ordinary Share."}],"balance_after":485000,"derivative":{"exercise_price":2.9,"expiration_date":"2033-02-01","underlying":"Ordinary Shares","underlying_shares":485000},"source":{"system":"sec-edgar","filing":"0001104659-23-025391","document":"tm237643-6_4seq1.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1828185/000110465923025391/tm237643-6_4seq1.xml","form_type":"4"}},{"id":1995193,"issuer":{"id":9597,"kind":"organization","name":"Barinthus Biotherapeutics plc.","symbol":"BRNS"},"owners":[{"id":38019,"kind":"person","name":"Enright William","position":1,"cik":"0001705564","reported_name":"Enright William","relationship":{"director":true,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Executive Officer"}}],"security":"Share Option (Right to Buy)","published_at":"2023-02-23T21:55:26.000Z","date":"2023-01-03","kind":"grant","acquired":true,"shares":440000,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F2","text":"This option shall vest and become exercisable in three equal annual installments, with the first installment vesting on January 3, 2024."},{"field":"derivative.underlying","element":"underlyingSecurityTitle","label":"F1","text":"The Ordinary Shares may be represented by American Depositary Shares, each of which currently represents one Ordinary Share."}],"balance_after":440000,"derivative":{"exercise_price":2.4,"expiration_date":"2033-01-03","underlying":"Ordinary Shares","underlying_shares":440000},"source":{"system":"sec-edgar","filing":"0001104659-23-024802","document":"tm237643-3_4seq1.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1705564/000110465923024802/tm237643-3_4seq1.xml","form_type":"4"}},{"id":1995139,"issuer":{"id":9597,"kind":"organization","name":"Barinthus Biotherapeutics plc.","symbol":"BRNS"},"owners":[{"id":83544,"kind":"person","name":"Brown Gemma","position":1,"cik":"0001947293","reported_name":"Brown Gemma","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Financial Officer"}}],"security":"Share Option (Right to Buy)","published_at":"2023-02-23T21:52:13.000Z","date":"2023-01-03","kind":"grant","acquired":true,"shares":33100,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F2","text":"This option shall vest and become exercisable in three equal annual installments, with the first installment vesting on January 3, 2024."},{"field":"derivative.underlying","element":"underlyingSecurityTitle","label":"F1","text":"The Ordinary Shares may be represented by American Depositary Shares, each of which currently represents one Ordinary Share."}],"balance_after":33100,"derivative":{"exercise_price":2.4,"expiration_date":"2033-01-03","underlying":"Ordinary Shares","underlying_shares":33100},"source":{"system":"sec-edgar","filing":"0001104659-23-024799","document":"tm237643-1_4seq1.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1828185/000110465923024799/tm237643-1_4seq1.xml","form_type":"4"}},{"id":1996214,"issuer":{"id":9597,"kind":"organization","name":"Barinthus Biotherapeutics plc.","symbol":"BRNS"},"owners":[{"id":83560,"kind":"person","name":"Griffiths Graham","position":1,"cik":"0001851630","reported_name":"Griffiths Graham","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Business Officer"}}],"security":"Share Option (Right to Buy)","published_at":"2023-02-23T16:56:44.000Z","date":"2023-01-03","kind":"grant","acquired":true,"shares":105000,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F2","text":"This option shall vest and become exercisable in three equal annual installments, with the first installment vesting on January 3, 2024."},{"field":"derivative.underlying","element":"underlyingSecurityTitle","label":"F1","text":"The Ordinary Shares may be represented by American Depositary Shares, each of which currently represents one Ordinary Share."}],"balance_after":105000,"derivative":{"exercise_price":2.4,"expiration_date":"2033-01-03","underlying":"Ordinary Shares","underlying_shares":105000},"source":{"system":"sec-edgar","filing":"0001104659-23-024805","document":"tm237643-4_4seq1.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1851630/000110465923024805/tm237643-4_4seq1.xml","form_type":"4"}},{"id":1996213,"issuer":{"id":9597,"kind":"organization","name":"Barinthus Biotherapeutics plc.","symbol":"BRNS"},"owners":[{"id":116539,"kind":"person","name":"Ellis Christopher","position":1,"cik":"0001851664","reported_name":"Ellis Christopher","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Operating Officer"}}],"security":"Share Option (Right to Buy)","published_at":"2023-02-23T16:54:18.000Z","date":"2023-01-03","kind":"grant","acquired":true,"shares":105000,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F2","text":"This option shall vest and become exercisable in three equal annual installments, with the first installment vesting on January 3, 2024."},{"field":"derivative.underlying","element":"underlyingSecurityTitle","label":"F1","text":"The Ordinary Shares may be represented by American Depositary Shares, each of which currently represents one Ordinary Share."}],"balance_after":105000,"derivative":{"exercise_price":2.4,"expiration_date":"2033-01-03","underlying":"Ordinary Shares","underlying_shares":105000},"source":{"system":"sec-edgar","filing":"0001104659-23-024801","document":"tm237643-2_4seq1.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1851664/000110465923024801/tm237643-2_4seq1.xml","form_type":"4"}},{"id":2022660,"issuer":{"id":9597,"kind":"organization","name":"Barinthus Biotherapeutics plc.","symbol":"BRNS"},"owners":[{"id":34812,"kind":"person","name":"Phillips Anne M.","position":1,"cik":"0001627680","reported_name":"Phillips Anne M.","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Share Option (Right to Buy)","published_at":"2023-02-10T21:39:04.000Z","date":"2022-06-15","kind":"grant","acquired":true,"shares":18604,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"One-third of the shares underlying this option shall vest and become exercisable on June 15, 2023, with the remainder vesting in 24 equal monthly installments thereafter."},{"field":"derivative.underlying","element":"underlyingSecurityTitle","label":"F2","text":"The Ordinary Shares may be represented by American Depositary Shares, each of which currently represents one Ordinary Share."}],"balance_after":18604,"derivative":{"exercise_price":4.27,"expiration_date":"2032-06-15","underlying":"Ordinary Shares","underlying_shares":18604},"source":{"system":"sec-edgar","filing":"0001104659-23-018607","document":"tm236344-4_5seq1.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1627680/000110465923018607/tm236344-4_5seq1.xml","form_type":"5"}},{"id":2022920,"issuer":{"id":9597,"kind":"organization","name":"Barinthus Biotherapeutics plc.","symbol":"BRNS"},"owners":[{"id":78627,"kind":"person","name":"Wright Robin","position":1,"cik":"0001851640","reported_name":"Wright Robin","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Share Option (Right to Buy)","published_at":"2023-02-10T16:44:00.000Z","date":"2022-06-15","kind":"grant","acquired":true,"shares":18604,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"One-third of the shares underlying this option shall vest and become exercisable on June 15, 2023, with the remainder vesting in 24 equal monthly installments thereafter."},{"field":"derivative.underlying","element":"underlyingSecurityTitle","label":"F2","text":"The Ordinary Shares may be represented by American Depositary Shares, each of which currently represents one Ordinary Share."}],"balance_after":18604,"derivative":{"exercise_price":4.27,"expiration_date":"2032-06-15","underlying":"Ordinary Shares","underlying_shares":18604},"source":{"system":"sec-edgar","filing":"0001104659-23-018613","document":"tm236344-6_5seq1.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1851640/000110465923018613/tm236344-6_5seq1.xml","form_type":"5"}},{"id":2022925,"issuer":{"id":9597,"kind":"organization","name":"Barinthus Biotherapeutics plc.","symbol":"BRNS"},"owners":[{"id":78630,"kind":"person","name":"Scheeren Joseph","position":1,"cik":"0001852070","reported_name":"Scheeren Joseph","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Share Option (Right to Buy)","published_at":"2023-02-10T16:40:48.000Z","date":"2022-06-15","kind":"grant","acquired":true,"shares":18604,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"One-third of the shares underlying this option shall vest and become exercisable on June 15, 2023, with the remainder vesting in 24 equal monthly installments thereafter."},{"field":"derivative.underlying","element":"underlyingSecurityTitle","label":"F2","text":"The Ordinary Shares may be represented by American Depositary Shares, each of which currently represents one Ordinary Share."}],"balance_after":18604,"derivative":{"exercise_price":4.27,"expiration_date":"2032-06-15","underlying":"Ordinary Shares","underlying_shares":18604},"source":{"system":"sec-edgar","filing":"0001104659-23-018609","document":"tm236344-5_5seq1.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1852070/000110465923018609/tm236344-5_5seq1.xml","form_type":"5"}},{"id":2022924,"issuer":{"id":9597,"kind":"organization","name":"Barinthus Biotherapeutics plc.","symbol":"BRNS"},"owners":[{"id":78628,"kind":"person","name":"Morgon Pierre A.","position":1,"cik":"0001851636","reported_name":"Morgon Pierre A.","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Share Option (Right to Buy)","published_at":"2023-02-10T16:36:56.000Z","date":"2022-06-15","kind":"grant","acquired":true,"shares":18604,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"One-third of the shares underlying this option shall vest and become exercisable on June 15, 2023, with the remainder vesting in 24 equal monthly installments thereafter."},{"field":"derivative.underlying","element":"underlyingSecurityTitle","label":"F2","text":"The Ordinary Shares may be represented by American Depositary Shares, each of which currently represents one Ordinary Share."}],"balance_after":18604,"derivative":{"exercise_price":4.27,"expiration_date":"2032-06-15","underlying":"Ordinary Shares","underlying_shares":18604},"source":{"system":"sec-edgar","filing":"0001104659-23-018602","document":"tm236344-3_5seq1.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1851636/000110465923018602/tm236344-3_5seq1.xml","form_type":"5"}},{"id":2022923,"issuer":{"id":9597,"kind":"organization","name":"Barinthus Biotherapeutics plc.","symbol":"BRNS"},"owners":[{"id":78629,"kind":"person","name":"Hammacher Alex","position":1,"cik":"0001851633","reported_name":"Hammacher Alex","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Share Option (Right to Buy)","published_at":"2023-02-10T16:35:22.000Z","date":"2022-06-15","kind":"grant","acquired":true,"shares":18604,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"One-third of the shares underlying this option shall vest and become exercisable on June 15, 2023, with the remainder vesting in 24 equal monthly installments thereafter."},{"field":"derivative.underlying","element":"underlyingSecurityTitle","label":"F2","text":"The Ordinary Shares may be represented by American Depositary Shares, each of which currently represents one Ordinary Share."}],"balance_after":18604,"derivative":{"exercise_price":4.27,"expiration_date":"2032-06-15","underlying":"Ordinary Shares","underlying_shares":18604},"source":{"system":"sec-edgar","filing":"0001104659-23-018595","document":"tm236344-2_5seq1.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1851633/000110465923018595/tm236344-2_5seq1.xml","form_type":"5"}},{"id":2022433,"issuer":{"id":9597,"kind":"organization","name":"Barinthus Biotherapeutics plc.","symbol":"BRNS"},"owners":[{"id":46694,"kind":"person","name":"DAWES KAREN A","position":1,"cik":"0001261506","reported_name":"DAWES KAREN A","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Share Option (Right to Buy)","published_at":"2023-02-10T16:34:04.000Z","date":"2022-06-15","kind":"grant","acquired":true,"shares":18604,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"One-third of the shares underlying this option shall vest and become exercisable on June 15, 2023, with the remainder vesting in 24 equal monthly installments thereafter."},{"field":"derivative.underlying","element":"underlyingSecurityTitle","label":"F2","text":"The Ordinary Shares may be represented by American Depositary Shares, each of which currently represents one Ordinary Share."}],"balance_after":18604,"derivative":{"exercise_price":4.27,"expiration_date":"2032-06-15","underlying":"Ordinary Shares","underlying_shares":18604},"source":{"system":"sec-edgar","filing":"0001104659-23-018593","document":"tm236344-1_5seq1.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1261506/000110465923018593/tm236344-1_5seq1.xml","form_type":"5"}},{"id":2143451,"issuer":{"id":9597,"kind":"organization","name":"Barinthus Biotherapeutics plc.","symbol":"BRNS"},"owners":[{"id":123291,"kind":"organization","name":"M&G Alternatives Investment Management Ltd","position":1,"cik":"0001891922","reported_name":"M&G Alternatives Investment Management Ltd","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}}],"security":"American Depositary Shares","published_at":"2022-10-04T17:03:49.000Z","date":"2022-09-30","kind":"other","acquired":false,"shares":4108752,"price":0,"value":0.0,"ownership":{"direct":false,"nature":"Please see footnote"},"footnotes":[{"field":"security","element":"securityTitle","label":"F1","text":"Each share representing one ordinary share."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F2","text":"The reported securities were held directly by Prudential Credit Opportunities SCSP, advised by M&G Alternatives Investment Management Limited. The reported securities may be deemed beneficially owned for the purposes of Section 13(d) of the Securities Exchange Act 1934 by M&G Alternatives Investment Management Limited as investment manager to these funds. The Reporting Person disclaims beneficial ownership of the securities for purposes of Rule 16a-1(a)(2) and this report shall not be deemed an admission that such Reporting Person is the beneficial owner of the securities for purposes of Section 16 of the Securities Exchange Act of 1934, as amended, or for any other purpose."}],"balance_after":0,"source":{"system":"sec-edgar","filing":"0001567619-22-018101","document":"doc1.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1828185/000156761922018101/doc1.xml","form_type":"4"}},{"id":2145843,"issuer":{"id":9597,"kind":"organization","name":"Barinthus Biotherapeutics plc.","symbol":"BRNS"},"owners":[{"id":100059,"kind":"organization","name":"M&G INVESTMENT MANAGEMENT LTD","position":1,"cik":"0000922898","reported_name":"M&G INVESTMENT MANAGEMENT LTD","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}}],"security":"American Depositary Shares","published_at":"2022-10-04T17:01:52.000Z","date":"2022-09-30","kind":"other","acquired":true,"shares":4108752,"price":0,"value":0.0,"ownership":{"direct":false,"nature":"Please see footnote"},"footnotes":[{"field":"security","element":"securityTitle","label":"F1","text":"Each share representing one ordinary share."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F2","text":"The reported securities are held directly by M&G ACS, advised by M&G Investment Management Limited. The reported securities may be deemed beneficially owned for the purposes of Section 13(d) of the Securities Exchange Act 1934 by M&G Investment Management Limited as investment manager to these funds. The Reporting Person disclaims beneficial ownership of the securities for purposes of Rule 16a-1(a)(2) and this report shall not be deemed an admission that such Reporting Person is the beneficial owner of the securities for purposes of Section 16 of the Securities Exchange Act of 1934, as amended, or for any other purpose."}],"balance_after":5197349,"source":{"system":"sec-edgar","filing":"0001567619-22-018100","document":"doc1.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/922898/000156761922018100/doc1.xml","form_type":"4"}},{"id":2149752,"issuer":{"id":9597,"kind":"organization","name":"Barinthus Biotherapeutics plc.","symbol":"BRNS"},"owners":[{"id":83544,"kind":"person","name":"Brown Gemma","position":1,"cik":"0001947293","reported_name":"Brown Gemma","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Financial Officer"}}],"security":"Share Option (Right to Buy)","published_at":"2022-09-28T20:05:16.000Z","date":"2022-09-26","kind":"grant","acquired":true,"shares":334000,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"The shares underlying this option shall vest and become exercisable in three equal annual installments, with the first installment vesting on September 15, 2023."},{"field":"derivative.underlying","element":"underlyingSecurityTitle","label":"F2","text":"The Ordinary Shares may be represented by American Depositary Shares, each of which currently represents one Ordinary Share."}],"balance_after":334000,"derivative":{"exercise_price":3.07,"expiration_date":"2032-09-26","underlying":"Ordinary Shares","underlying_shares":334000},"source":{"system":"sec-edgar","filing":"0001104659-22-103706","document":"tm2226822-1_4seq1.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1828185/000110465922103706/tm2226822-1_4seq1.xml","form_type":"4"}},{"id":2173009,"issuer":{"id":9597,"kind":"organization","name":"Barinthus Biotherapeutics plc.","symbol":"BRNS"},"owners":[{"id":83560,"kind":"person","name":"Griffiths Graham","position":1,"cik":"0001851630","reported_name":"Griffiths Graham","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Business Officer"}}],"security":"Ordinary Shares","published_at":"2022-08-26T16:27:10.000Z","date":"2022-08-25","kind":"sale","acquired":false,"shares":10000,"price":7.387,"value":73870.0,"ownership":{"direct":true},"footnotes":[{"field":"security","element":"securityTitle","label":"F1","text":"The Ordinary Shares may be represented by American Depositary Shares, each of which currently represents one Ordinary Share."},{"field":"price","element":"transactionPricePerShare","label":"F2","text":"The price reported in column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $7.34 - $7.44. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote."}],"balance_after":104209,"source":{"system":"sec-edgar","filing":"0001104659-22-095144","document":"tm2224672-2_4seq1.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1851630/000110465922095144/tm2224672-2_4seq1.xml","form_type":"4"}},{"id":2173008,"issuer":{"id":9597,"kind":"organization","name":"Barinthus Biotherapeutics plc.","symbol":"BRNS"},"owners":[{"id":116539,"kind":"person","name":"Ellis Christopher","position":1,"cik":"0001851664","reported_name":"Ellis Christopher","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Operating Officer"}}],"security":"Share Option (Right to Buy)","published_at":"2022-08-26T16:26:01.000Z","date":"2022-08-25","kind":"exercise","acquired":false,"shares":39176,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F5","text":"This option is fully vested and exercisable as of the date hereof. The exercise price of this option is GBP 0.000324 per share and has been converted from pounds sterling to U.S. dollars using an average exchange rate of $1.3269 to GBP 1.00 on December 31, 2019."},{"field":"derivative.underlying","element":"underlyingSecurityTitle","label":"F1","text":"The Ordinary Shares may be represented by American Depositary Shares, each of which currently represents one Ordinary Share."}],"balance_after":980,"derivative":{"exercise_price":0.0004,"expiration_date":"2028-02-16","underlying":"Ordinary Shares","underlying_shares":39176},"source":{"system":"sec-edgar","filing":"0001104659-22-095142","document":"tm2224672-1_4seq1.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":7,"url":"https://www.sec.gov/Archives/edgar/data/1851664/000110465922095142/tm2224672-1_4seq1.xml","form_type":"4"}},{"id":2173007,"issuer":{"id":9597,"kind":"organization","name":"Barinthus Biotherapeutics plc.","symbol":"BRNS"},"owners":[{"id":116539,"kind":"person","name":"Ellis Christopher","position":1,"cik":"0001851664","reported_name":"Ellis Christopher","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Operating Officer"}}],"security":"Share Option (Right to Buy)","published_at":"2022-08-26T16:26:01.000Z","date":"2022-08-24","kind":"exercise","acquired":false,"shares":450,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F5","text":"This option is fully vested and exercisable as of the date hereof. The exercise price of this option is GBP 0.000324 per share and has been converted from pounds sterling to U.S. dollars using an average exchange rate of $1.3269 to GBP 1.00 on December 31, 2019."},{"field":"derivative.underlying","element":"underlyingSecurityTitle","label":"F1","text":"The Ordinary Shares may be represented by American Depositary Shares, each of which currently represents one Ordinary Share."}],"balance_after":40156,"derivative":{"exercise_price":0.0004,"expiration_date":"2028-02-16","underlying":"Ordinary Shares","underlying_shares":450},"source":{"system":"sec-edgar","filing":"0001104659-22-095142","document":"tm2224672-1_4seq1.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":6,"url":"https://www.sec.gov/Archives/edgar/data/1851664/000110465922095142/tm2224672-1_4seq1.xml","form_type":"4"}},{"id":2173006,"issuer":{"id":9597,"kind":"organization","name":"Barinthus Biotherapeutics plc.","symbol":"BRNS"},"owners":[{"id":116539,"kind":"person","name":"Ellis Christopher","position":1,"cik":"0001851664","reported_name":"Ellis Christopher","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Operating Officer"}}],"security":"Ordinary Shares","published_at":"2022-08-26T16:26:01.000Z","date":"2022-08-25","kind":"sale","acquired":false,"shares":25000,"price":7.0683,"value":176707.5,"ownership":{"direct":true},"footnotes":[{"field":"security","element":"securityTitle","label":"F1","text":"The Ordinary Shares may be represented by American Depositary Shares, each of which currently represents one Ordinary Share."},{"field":"price","element":"transactionPricePerShare","label":"F4","text":"The price reported in column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $7.04 - $7.12. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote."}],"balance_after":75,"source":{"system":"sec-edgar","filing":"0001104659-22-095142","document":"tm2224672-1_4seq1.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":5,"url":"https://www.sec.gov/Archives/edgar/data/1851664/000110465922095142/tm2224672-1_4seq1.xml","form_type":"4"}}],"next_cursor":"2022-08-26T16:26:01.000000Z,2173006"}